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A patient-reported outcome (PRO) is a type of outcome reported directly from patients, 
and it has been widely used in medical research and clinical trials to measure a patient’s 
symptoms, health-related quality of life, physical functioning, and health status.  Previous studies 
have linked PROs to survival outcomes, but most of them only used the PRO information at 
baseline or at a specific clinical time point [1, 2].  Even though some of these studies collected 
longitudinal PROs, only few of them evaluated the association between the longitudinal PROs 
and a survival outcome.  One of the major challenges in longitudinal PRO studies is to address 
the individual heterogeneity in PRO repeated measurements.  Due to the fact that PRO is 
reported directly from patients, and different patients may have different experiences, 
longitudinal PROs have been often observed with individual heterogeneity, yet current methods 
[3-5] are not able to account for the individual heterogeneity.  Therefore, in this research, we 
developed three methods using two-state Continuous-Time Markov Chain (CTMC) to 
summarize longitudinal PRO.  The primary summary used is the estimated state transition rates, 
which serve as summary statistics to depict longitudinal PRO patterns at the individual level.  
These transition rates can also be incorporated into survival models as predictors or into factor 
analysis as observed variables.  Specifically, in the first two papers, we developed prognostic 
models that contained baseline covariates and a longitudinal process in two survival models, 
Weibull Regression and Cox Proportional Hazard Regression, with different estimation 
approaches.  Simulation studies were conducted to validate the proposed methods, and the 
proposed models were then applied to two PRO studies separately, with both using repeated 
PRO measurements during the treatment period in cancer patients to predict the survival 
outcomes that happened after the treatment.  In the third paper, we then integrated two-state 
CTMC with factor analysis to evaluate the usage of CTMC in PRO symptom clustering.  This 
study showed that CTMC could well summarize the longitudinal PRO information during the 
treatment period of cancer patients.  The underlying construct of patient-reported symptoms had 
also met our expectations from clinical experience. 
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1. BACKGROUND 
1.1 Introduction of Patient-Reported Outcome 
1.1.1 Patient-Reported Outcome in Cancer Research 
Patient-reported outcome (PRO) is a type of outcome that is measured not from 
physicians or caregivers, but directly from patients themselves.  It is based on the patients’ 
perceptions of the disease and treatment [6, 7].  Generally, PRO includes measures of symptoms 
(single or multi-dimension), health-related quality of life (HRQoL), physical functioning, and 
health status [6, 8].  
Patient-reported outcomes (PROs) have been widely used in biomedical research, 
especially in mental health, chronic illness, and oncology [9-12].  In clinical trials or 
observational studies, PROs have been used in many aspects and have provided different 
functionalities to researchers.  For example, PROs have been used as a tool to determine the 
eligibility of patients in the enrollment process when the screening outcome can only be reported 
by patients [7].  Also, PROs have been used to confirm and monitor disease status.  Because 
cancer patients always experience multiple symptoms (e.g., pain, fatigue, and distress) during 
their treatment, PROs can play a role as a surrogate to monitor patients’ reactions to the 
treatment and provide responsive symptom information to clinicians [13].  Additionally, to 
explain low patient compliance rates in clinical trials, PRO measures are often used [7].  For 
example, patients who have severe symptoms may drop out from clinical trials early.  PRO is 
also widely used as a study endpoint because it can provide a unique perspective on treatment 
effectiveness [14-16].  Studies have used PROs as primary endpoints or exploratory endpoints in 
clinical trials when the research questions can only be measured by PROs.  When the treatment 
has a negative implication for other aspects of life (e.g., side effects), PROs can also assess the 
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impact of the treatment on the patient’s quality of life.  Furthermore, Basch et al. [17] showed 
that a patient-reported symptom monitoring group had better survival compared to a usual care 
group while controlling other demographic and clinical factors.  Additionally, the development 
of a new biosimilar compound may need PROs to distinguish the benefit from the standard drugs 
when the biological benefits are comparable.  Therefore, it is believed that PROs will be as 
important as other types of outcomes, such as clinical outcomes, physiological outcomes, and 
care-giver reported outcomes.  In fact, in the past decades, PROs have been extensively applied 
to observational studies and clinical trials. The European Medicine Agency (EMA) published a 
guideline for the pharmaceutical industry, in which PRO is suggested to be included in oncology 
clinical trials to assist benefit-risk assessment and therapeutic claims [6, 18].  Similarly, the US 
Food and Drug Administration (FDA) released a guideline that recommended PROs for clinical 
trials and outlined the properties and components of PRO instruments [7]. 
 
1.1.2 Patient-Reported Outcome Instruments 
To better understand the difference between symptoms and HRQoL and elements of a 
PRO instrument, this section will introduce properties of a PRO instrument and some commonly-
used PRO instruments in oncology.    
Patient-reported Outcome Symptoms and Health-Related Quality of Life 
PRO symptoms and HRQoL are often studied and discussed together, yet they are not the 
same.  A symptom is a one-dimensional property related to a disease or treatment status that is 
directly reported from patients.  On the other hand, HRQoL is a multi-dimensional measure that 
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consists of several physical, psychological, social, economical factors, disease or treatment 
symptoms, and cultural set-up [19].      
Properties of PRO Instruments 
PRO instruments are the tools used to measure PROs, e.g., symptoms or HRQoL related 
to a disease or treatment.  According to Deshpande et al. [19], a good PRO instrument should 
possess the following properties:  First, it should be specific to the concept being measured [20].  
Depending on the purpose of the instrument, a PRO instrument usually only measures one 
general concept of a disease or treatment.  Second, a good PRO instrument should be based on 
an end-point model, a hierarchical model that considers all types of endpoints, non-PRO 
assessment and PRO assessment, to meet the requirements of a clinical trial’s objective, study 
design, and data analysis plan [20].  For example, a clinical trial following an end-point model 
may contain three types of endpoints that can be measured from a bio-chemical exam (non-PRO 
assessment), physical exam (non-PRO assessment), and symptoms of the disease (PRO 
assessment).  Third, a good PRO instrument should have conceptual equivalence, which means 
the instrument should measure the same concept equivalently in different languages and cultures.  
Fourth, a good PRO instrument should consist of a conceptual framework, an “item-domain-
concept” structure that defines how concepts should be measured by the instrument [20].  For 
example, a general QoL concept can be defined by several domains (physical, emotional, and 
social), and each domain can be measured by several items.  Fifth, a good PRO instrument 
should have easy and specific measurement properties and contain an optimum number of items.  
The scale system for the measurement and the number of total items in an instrument should be 
easy to understand and complete for patients.  Last, a good PRO instrument should maintain 
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patient confidentiality.  Patient confidentiality is important for all kinds of studies.  So, a good 
instrument should only collect the information that is necessary for each study objective.    
Common Oncology PRO Instruments  
A number of PRO instruments have been designed for oncology studies.  PRO 
instruments that are commonly used in cancer clinical trials are as follows: 
EORTC-QLQ-C30 
 Developed by the European Organization for Research and Treatment of Cancer 
(EORTC), the EORTC quality of life core questionnaire (QLQ-C30) consists of 30 items [21, 
22].  It is a general instrument that can be applied to all types of cancer patients through 5 
functional scales (physical, role, emotional, cognitive, and social), 9 single items, and two items 
on global health status and QoL.  It uses a 4-point numerical rating scale (not at all, a little, quite 
a bit, very much) in most questions and a 7-point numerical scale for global health status/QoL 
items.  The raw score in EORTC-QLQ-C30 can be transformed to a 0-100 scaling by following 
its scoring procedure.  A higher functional scale or QoL represents a healthy level of functioning 
or higher QoL; while a higher symptom item represents a higher level of 
symptomatology/problems.  This instrument also has several modules to supplement the core 
EORTC-QLQ-C30.  For example, QLQ-BR-23 contains 23 additional items measuring disease 
symptoms, side effects of a treatment, body image, sexual functioning, and future perspectives 
for breast cancer patients.  A QLQ-H&N-35 is a module for head and neck cancer patients that 
measures symptoms and side effects of a treatment, social function, and body image/sexuality 
through 35 additional questions.  The scoring approaches for these modules are identical with 
that for QLQ-C30. Thus, these modules can be easily applied to data analyses and reporting in 
5 
 
cancer studies.  The interpretation of scoring can be done by reporting the raw score in each 
functional scale or single symptom/QoL item, by comparing the difference of score (e.g., 
Cohen’s effect size) between groups, or by comparing scores at different time points. 
EQ-5D-5L 
The EuroQol Group developed EQ-5D-5L and released it in 2009 [23, 24].  It is a 
modified version based on the previous EQ-5D-3L, but EQ-5D-5L has improved the 
instrument’s sensitivity and reduced the ceiling effects.  This instrument contains 5 domains 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 5-level 
scale (no problems, slight problems, moderate problems, severe problems, and extreme 
problems) and a visual analogue scale (EQ VAS) with a 0-100 scaling.  Specifically, the EQ 
VAS is a scale that asks the patient to mark their health condition of that day on a ruler graph, 
ranging from “worst possible” to “best possible” health.  The report for EQ-5D-5L may contain 
the distribution (frequency) of each domain, an overall index calculated from the domains (range 
in -0.1 to 1), and the EQ VAS.     
PRO-CTCAE 
The Patient-Reported Outcomes version of the Common Terminology Criteria for 
Adverse Events (PRO-CTCAE) [25, 26] was developed by National Cancer Institute (NCI) to 
capture the symptomatic adverse events (e.g., side effects of a treatment) in cancer patients 
enrolled in clinical trials.  It is recommended to be used with a Common Terminology Criteria 
for Adverse Events (CTCAE) score graded by physicians.  PRO-CTCAE includes an item library 
that consists of 124 items for 78 symptomatic toxicities.  Selection of items from the library is 
usually based on previous studies or previous pre-clinical data.  It uses a 0-4 scale for each item, 
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and each symptom is measured through three attributes: frequency, severity, and/or interference.  
The analysis of PRO-CTCAE depends on the design of each study, but every toxicity item is 
interpreted independently.   
FACT-G 
 Functional Assessment of Chronic Illness Therapy (FACIT) developed Functional 
Assessment of Cancer Therapy – General (FACT-G) that collects core quality of life items from 
patients [27, 28].  It consists of 27 items in 4 domains (physical, social/family, emotional, and 
functional well-being), and it is usually applied to cancer and other chronic diseases (e.g., 
HIV/AIDS).  It uses a 5-point scaling and contains some reversed items.  A higher score in 
FACT-G (range in 0-108) means a better quality of life.  FACIT also provides modules for 
various forms of cancer, which include an additional section with disease specific questions.  For 
example, FACT-Hep is an instrument for patients with hepatobiliary cancer (liver, bile duct, and 
pancreas), and FACT-O is one for patients with ovarian cancer.  In these modules, a Trial 
Outcome Index (TOI), a summary of 4 domains in FACT-G, and the subscale from a specific 
disease is usually reported to reflect the overall physical and functional condition of a patient.   
SF-36 
RAND Health Care developed Short Form Health Survey (SF-36) that contains 36 items 
to measure patients’ generic quality of life [29, 30].  SF-36 is part of the Medical Outcome Study 
(MOS), a multi-site study that explaines variations in patient outcomes.  SF-36 contains 8 health 
concepts: physical functioning, bodily pain, role limitations due to physical health problems, role 
limitations due to personal or emotional problems, emotional well-being, social functioning, 
energy/fatigue, and general health perceptions.  In this instrument, it uses a scaling system 
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ranging from a 2-point scale to a 6-point scale.  It interprets the results of each health concept 
(range in 0-100), and a higher score means a more favorable health state.      
MDASI 
The MD Anderson Symptom Inventory (MDASI) is a multi-symptom PRO instrument 
developed by The University of Texas MD Anderson Cancer Center [31, 32].  MDASI-Core 
contains 13 core symptom items and 6 interference items using a 0-10 numerical rating scale, 
where 0 represents no symptom present, and 10 represents the symptom that is as bad as a patient 
can imagine.  The simple feature and design make this instrument easy to understand, and it can 
be completed in 3-5 minutes.  MDASI also comprises multiple modules that are designed for 
different cancer diseases and treatment-specific purposes.  For example, MDASI-BT is a module 
for brain tumor patients that includes items in MDASI-Core and additional items specifically 
related to brain tumor.  The interpretation of MDASI depends on the study objective.  Both 
single-item scoring (score in 0-10) and composite scoring (e.g., mean of most 5 severe symptom 
items) are widely used in clinical studies.  In this dissertation, given the data availability, MDASI 
will be the only PRO instrument used to measure cancer patients’ symptom burden during the 
treatment period. 
 Most PRO instrument manuals provide a recommendation for PRO result presentation or 
instructions of PRO instrument administration.  Some instruments can report the result in single 
symptom item, while others can only report the subscale of each domain or a total index after 
designed transformation.  Besides, the frequency of administering a PRO instrument is also 
important, and it depends on the recall period.  For example, the recall period for EQ-5D-5L is 
the day when patients complete the survey.  MDASI, however, has a recall period for the last 24 
hours, and EORTC-C30, FACT-G, PRO-CTCAE have a recall periods for the past week (7 
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days).  Some instruments suggest a weekly collection during the study; other depend on the need 
and design of the study.  The more frequent a PRO instrument is distributed, the more costly the 
study will become.  In some studies [33], PROs are collected only 2-3 times across the study 
period, and PRO results are compared in a cross-sectional manner.  For example, a QoL score at 
baseline (before treatment) can be compared with the QoL score after the treatment.  However, 
more researchers start to collect longitudinal PROs (more than 3 times of collection) in their 
studies [34, 35] because longitudinal PRO can better explain patients’ experience on the cause of 
disease and treatment.  The analysis of longitudinal PRO results will be discussed in the 
following section.   
 
1.1.3 Longitudinal PRO Analysis 
 Longitudinal PROs can provide more symptom and HRQoL information realted to the 
disease, drugs, and operations involved.  For example, a comprehensive deisgn of longitudinal 
PRO collections records PRO at baseline, treatment cycles (weekly or bi-weekly), and post-
treatment follow-up (bi-weekly, monthly, or every 6 months) [36].  The PRO instruments; 
therefore, can measure symptom change over the study period, providing detailed information on 
the difference before and after the treatment; and capturing the variation of symptoms at a 
meaningful clinical time point.   
The trajectory of longitudinal PRO may not always be linear.  In most of the 
observational studies on cancer with chemotherapy [37, 38], a weekly measured PRO tends to 
show a non-linear pattern (waves) during the weeks when patients receive the chemotherapy.  
This type of data can indicate whether a symptom is changed by the influence of the disease or 
by the effectiveness/burden of the treatment.      
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Longitudinal PROs as Outcomes  
There are many ways to analyze longitudinal PROs; however, most of the methods 
consider longitudinal PROs as outcome variables.  For example, Fairclough [39] described the 
common considerations for analyzing a longitudinal PRO as an outcome in her book; and 
provided examples and programing codes with detailed instructions.  Below are some examples 
of longitudinal PROs analyzed as outcomes: 
Lin et al. [40] used a Linear Mixed-effect Model (LMM) to analyze longitudinal HRQoL 
data from patients who had lumber spine surgery in Taiwan.  A series of PRO instruments were 
distributed (e.g., Taiwanese version of World Health Organization Quality of Life-BREF and 
Numerical Rating Scale for leg and back pain) to the patients 1 week before their lumber spine 
surgery, as well as during the first, sixth, and twelfth month after the surgery.  Two domains in 
the HRQoL, physical health and social health, were fitted in the LMM with random intercept and 
random slope at a subject level to account for the variation within subjects.  Lin et al. found 
neurological functions, sleep quality, and depressive symptoms were the key factors affecting the 
QoL.  This is a typical example that treats longitudinal PRO as a repeated outcome, and how it is 
analyzed directly in a statistical model (LMM).  In fact, because of the simplicity of the 
modeling and the clarity of interpretation and model assumption, LMM has been widely used in 
PRO research.  
Another approach to analyzing longitudinal PROs is to transform longitudinal 
information into a one-dimensional variable and analyze it using regular models depending on 
the type of the transformed variable.  For example, Shi et al. [41] showed an example using 
Group-Based Trajectory Modeling (GBTM) to transform longitudinal PROs into binary or 
ordinal variables, and then these variables were treated as outcomes in an (ordinal) logistic 
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regression.   The GBTM is a model often used in psychology to identify clusters of subjects that 
follow a particular pattern (trajectory) related to the outcome over time.  Shi et al. applied the 5 
most severe symptom items (taking mean of 5 items) to GBTM and determined 2 or 4 groups of 
patients that followed the distinguished trajectories.  Once the clustering of subjects was 
identified, the predictors to this outcome were examined by the Generalized Linear Model 
(GLM).  Comparing with Lin et al.’s approach, this approach is based on the assumption that 
subjects have different patterns (groups) of longitudinal PROs, while Lin et al. [40] assumed 
their longitudinal PROs followed a general linear trend.  
PROs as Covariates 
 Other studies treat PROs as covariates and investigate the association between PROs and 
one type of outcome.  For example, Quinten et al. [42] suggested the patients-reported symptoms 
(measured from EORTC-QLQ-C30) plus clinical rating (CTCAE) could better predict overall 
survival.  They used data from 14 clinical trials that compared models with or without PROs in 
the Cox Proportional Hazard Model using Harrell concordance index (C-index).  It turned out 
that models with both patent-reported symptoms and clinical-rated variables showed a higher C-
index value.   
Armstrong et al. [43] also showed how PROs could be treated as covariates to predict the 
overall survival in patients with brain tumors.  They linked the PROs (using both EORTC-QLQ-
C30/BN20 and MDASI-BT) to examine the progression-free survival (PFS) and overall survival 
(OS) in a phase III clinical trial.  They found that PROs were associated with the risk of OS and 
PFS.  Besides, higher symptom burden on patients showed a higher risk of OS and PFS, while a 
higher QoL score showed a lower risk of OS and PFS. 
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However, most studies only used PROs at a specific time point as covariates in their 
model.  None has applied longitudinal PROs as covariates directly in models to predict 
outcomes.  Therefore, in this dissertation, we want to develop methods that incorporate 
longitudinal PROs as covariates in survival models.     
 
1.2 Models for Longitudinal covariates 
General Approaches to Repeated Measurements 
Longitudinal data analysis has been developed for years when the structure of the data 
includes repeated measurements.  The mixed-effects model and marginal model are the most 
popular methods applied to longitudinal data.  Among these methods, the mixed-effects model 
has used quite widely because it models characteristics on subject specific interpretation.  It can 
incorporate fixed-effects, random effects, and time-dependent covariates in the model while 
accounting for the correlation from repeated outcomes (continuous or categorical type).   
In contrast, survival analysis (also known as “time-to-event” type of data) also collects 
information over time, but it models the survival outcome as a function of the covariates.  
Besides, time-dependent covariates can be included in the survival model when the covariates 
are assumed to be measured without error.  For more information about general longitudinal 
analysis and survival analysis, please read Diggle et al. [44] and Klein and Moeschberger’s [45] 
books.   
Joint Models for Longitudinal Outcomes  
 Joint modeling is often used when two or more outcomes (/processes) are correlated or 
associated.   The main advantage of this modeling technique is its ability to reduce the bias of 
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estimation [46].  When one of the outcomes is a time-to-event variable, modeling a longitudinal 
process and a time-to-event outcome can improve the inference for both outcomes [47, 48] 
because the relationship of both outcomes is considered.  Several methods modeling a time-to-
event outcome and longitudinal outcomes are discussed in Hickey’s research [47] including the 
mechanism of joint modeling.  One popular type of joint model for longitudinal data and the 
time-to-event outcome is expressing survival outcomes in hazard function (e.g., Cox 
Proportional Hazard (Cox PH) model) [49].  The difference between groups (e.g., a binary 
variable) or a unit increment in a continuous variable can be easily interpreted as a risk increase 
or decrease to the survival event.  For example, Tsiatis and Davidian [5] proposed a joint model 
modeling longitudinal data (as covariates) as a function of time in the Cox PH model; and 
estimating parameters from the partial-likelihood.   
 Another class of longitudinal data in joint modeling deals with situations when the 
outcome is not time-to-event.  For example, Wang et al. [50] proposed a joint model that is a 
combination of a longitudinal model and a generalized linear model (GLM).  The first submodel 
is a random-effect model for repeated measurements, and the second one (considered as the 
primary model) is a GLM that takes random effects from the first submodel as covariates.  The 
limitation of this model is that the normality assumption for longitudinal covariates (random 
effects in the primary model) is not applicable to most real world situations.  Wang and Huang 
[51] and Li [52] modified the method and proposed similar methods that did not require the 
distribution assumption for the random effects, but through the longitudinal process.  In 
summary, these models [50-52] manage the longitudinal process as covariates and treat the 
process as a continuous variable in the primary model (e.g., a GLM).  It is true that one or more 
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features from the longitudinal submodel may also be evaluated in the primary models; however, 
not all of these features will represent individual behaviors.   
Functional Data Analysis 
 Another category of analyzing longitudinal covariates is through dimension reduction.  
When the longitudinal data include multiple variables, an approach to analyze this type of data is 
using Functional Data Analysis (FDA) while treating longitudinal data as smoothed curves, 
surfaces, or even hypersurfaces [53-56].  The concept here is to extract the proper information 
from the larger dimensions and compress it into smaller features.  Functional Principal 
Component Analysis (FPCA) is one of the FDA techniques that select meaningful components 
from the multiple longitudinal covariates.  FPCA also needs to select suitable basis functions 
(usually expects an orthogonal relationship amongs the features) and to determine the number of 
eigenfunctions to be chosen.  For more information, Ramsy [55] provides a comprehensive 
introduction and detailed statistical methodology in FDA. 
 
1.3 Markov Chain as Covariate Processes 
Markov Chain models have been used to study the progression process for neurological 
diseases such as Alzheimer's disease [57, 58] and Parkinson's disease [59, 60] because the nature 
of these diseases’ process can be assumed to follow the Markov Property.  The Markov Property 
is that for a collection of events, the state of a future event only depends on the current state, not 
the past state.  Therefore, the Markov Chain, a collection of variables over time that follows the 
Markov Property, is usually considered as an outcome in the study.  Karisson [61] used the first-
order Markov model to describe the change of sleep level (lighter sleep and deeper sleep) from 
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patients who had insomnia with comparison of treatment effect.  However, not many studies in 
the literature modeled the longitudinal process as a covariate and integrated it in the outcome of 
interest.   
Ho [62] modeled a longitudinal DNA-damage process as a Discrete Time Markov Chain 
(DTMC) to predict the occurence of lung cancer in a case-control study.  This method used the 
information that is repeatedly measured from genetic testing and modeled it as DTMC with 
transition probabilities estimated, and then applied these traisition probabilities in a logistic 
regression to esitmate the odds of the lung cancer.  Later on, Rubin et al. [63] extended this 
concept to the Continuous Time Markov Chain (CTMC) and modeled longitudinal intracranial 
pressure (ICP) with CTMC as covariates in the logistic regression to predict the status of patients 
with traumatic brain injuries.  In constrast to Ho and Rubin’s research, our proposed models in 
this dissertation will model longitudinal PROs as CTMC and then use the transition rates as 
covariates in a survival model framework.  To the best of our knowledge, no research published 
has ever applied CTMC to the longitudinal PRO data analysis.   
 
1.4 Public Health Significance 
The patient-reported outcome (PRO) is a tool that has been widely applied to biomedical 
research and clinical trials, and it is expected to be used more intensively in the future.  Hassett et 
al. [36] outlined the high-priority topics that were discussed during the 2012 American Society 
of Clinical Oncology (ASCO) Quality Care Symposium, and developing patient-centered quality 
measures is one of them.  Symptom measurement in cancer patients also needs to be conducted 
more comprehensively before, during, and after the treatment.   Therefore, the methodology that 
can utilize the information of longitudinal PROs in cancer studies is important; especially when 
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no methodology has linked longitudinal PROs with survival type of outcome in single statistical 
technique.  The proposed methods in this dissertation fill the gap in current PRO cancer research 
to fully link the patients-reported symptom burden experience in the treatment period with the 
overall survival. 
Furthermore, our prognostic models have significant impacts on clinical research and real 
world clinical practices especially when the concept of personalized medicine is a common goal 
to achieve.  In particular, our prognostic models can add value to treatment decisions, quantify 
the disease status, identify the patient’s condition, and predict clinical outcomes.  Basch et al. 
[17, 64] reported that routine symptom monitoring could prolong the survial time when 
compared to a usual care group without PRO monitoring because caregivers could respond to the 
patients when PRO symptom burden increment was detected.  The caregivers could then provide 
symptom management conselling, supportive medications, chemotherapy dose modifications, 
and referrals to doctors.  As a result, a methodology that can analyze PRO monitoring data (a 
longitudinal PRO structure) is essential and is useful when the primary outcome of interest is 
survial.  We expect the proposed methodologies to provide clinicians meaningful and 
interpretable results on the association between longitudinal PROs and survival outcome.  It is 
also believed that these methods could improve quality care of cancer patients in the future. 
 
1.5 Specific Aims 
The specific aims of this research study are described as follows: 
Aim 1.  To develop a fully-parametric time-to-event model using a two-state continuous-
time Markov Chain (CTMC) as predictors and other clinical/demographic risk factors as 
covariates. 
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In this aim, a joint model of full-parametric survival model that follows a Weibull 
distribution and a two-state CTMC was developed when the primary study outcome is the “time” 
to an event (e.g., overall survival time).  This approach models a longitudinal patient-reported 
outcome (PRO) measured during the treatment period as a CTMC to predict a survival outcome 
(survival time) that occurred after the treatment period.  The focus of this aim is to evaluate the 
prognostic value of a single longitudinal PRO score (a single item score) dichotomized as 
none/mild or moderate/severe to overall survival time.  Other covariates, such as demographic 
and clinical variables, can be adjusted in the survival submodel as well as in the CTMC 
submodel.  The sets of covariates adjusted in each submodel can contain different components of 
variables.  This method was applied to an observational study of non-small cell lung cancer 
(NSCLC) patients (named as NSCLC study), recruited from 2004-2009 at The University of 
Texas MD Anderson Cancer Center.   
 
Aim 2.  To develop a semi-parametric time-to-event model using a two-state continuous-
time Markov Chain (CTMC) as predictors and other clinical/demographic risk factors as 
covariates. 
In this aim, a joint approach of semi-parametric survival model and a two-state CTMC 
was developed when the primary study outcome is “risk” of the event (e.g., the risk of death in 
overall survival or risk of a disease progression).  A longitudinal PRO measured during treatment 
period was modeled as a CTMC to predict a survival risk using Cox proportional hazard model 
when the survival event occurs after the treatment period.  This aim targets the association 
between a longitudinal PRO score and risk of a survival event.  Similarly, as that in Aim 1, the 
sets of covariates included in the survival submodel and CTMC submodel can consist of 
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different variables.  This method was applied to an observational study of head and neck (HN) 
cancer patients (named as HN study), recruited from 2006-2007 at The University of Texas MD 
Anderson Cancer Center.   
 
Aim 3.  To conduct factor analysis of multiple two-state continuous-time Markov Chains 
(CTMCs) on individual longitudinal patient-reported outcomes.   
Each longitudinal PRO was modeled as two-state CTMC, and their transition rates were 
utilized for factor analysis that identified the latent factor on PRO items.  Unlike most studies 
that applied factor analysis to PRO items at a single occasion, we summarized each longitudinal 
PRO as CTMC by its transition rates and applied to factor analysis to reduce dimensions of 
longitudinal PROs.  This method was applied to data from HN studies.  The factors of symptoms 
provided hidden information on the sources of symptom burden and classification of symptom 
items such as treatment-related or disease-induced items. 
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2. Journal Article 1 
A Joint Model of Time to Event and Continuous-Time Markov Chain 
Statistics in Medicine 
Keywords: Continuous-Time Markov Chain (CTMC), longitudinal data analysis, patient-
reported outcome (PRO), survival analysis, Weibull regression 
 
2.1 Background 
In biomedical research, linking a patient’s longitudinal measurements to time-to-event 
types of outcome is essential since patients’ repeated measurements may contain more 
information on impact from disease and/or treatment.  Available approaches so far include a 
proportional hazard model with time-dependent covariates [1-3] and a joint model that comprises 
a longitudinal model and a survival model [4, 5].  In these two approaches, the former evaluates 
time-dependent covariate effects by truncating time-to-event to pieces based on the time points 
when covariates change, but it does not take into account any information of the longitudinal 
pattern of covariates.  The latter approach, on the other hand, models a longitudinal covariate as 
an overall trend and specifies the correlated nature of both outcomes, and the longitudinal 
submodel may include another set of covariates that are correlated to the longitudinal outcome 
resulting in a more complex model structure.  However, when individual heterogeneity exists in 
longitudinal measurements, neither of these two approaches could adequately fit the data.  Under 
such circumstance, a more flexible method, such as Markov Chain [6, 7] at an individual patient 
level, may be more suitable to explain the distinct trajectories at individuals.  Therefore, in this 
study, we propose a joint Continuous-Time Markov Chain (CTMC) and Weibull model (also 
called Weibull Regression model [2, 3]) that treats the transition rates of CTMC as covariates in 
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Weibull Model to predict a survival outcome that happens after the longitudinal process, while 
both submodels permit other baseline information as covariates. 
Joint Models for Longitudinal Covariates and Time-to-event Outcome 
Joint modeling is regularly applied when two or more outcomes or processes are 
associated, and their relationship with other covariates needs to be simultaneously considered.  
The major advantage of this modeling technique is its ability to reduce estimation bias [8].  
Moreover, modeling a longitudinal process and a time-to-event outcome can improve the 
inference for both outcomes [5, 9] because this model is able to consider the relationship of both 
outcomes.  In the literature, several methods modeling a time-to-event outcome and longitudinal 
outcomes including the mechanism of the joint modeling have been discussed in Hickey’s 
research [9].  Tsiatis and Davidian [4] also proposed a joint model modeling longitudinal data (as 
covariates) as a function of time in the Cox PH model and estimated parameters from the partial-
likelihood.  Nevertheless, these models do not address change of the longitudinal process over 
time at the individual level. 
Markov Chain in Medical Research 
Markov Chain models have been used to study the progression process for neurological 
diseases such as Alzheimer's disease (AD) [10, 11] and Parkinson's disease [12, 13] because the 
nature of these diseases’ process can be appropriately assumed to follow the Markov Property, in 
which the states of future events only depend on the current state, not the past state.  Therefore, 
Markov Chain, a collection of variables over time that follows the Markov Property, is usually 
considered as a longitudinal outcome in medical studies.  For example, the first-order Markov 
model has been used to describe the change of sleep level (lighter sleep vs. deeper sleep) from 
patients who had insomnia, and the treatment showed an improved time in sleep [14].  Wu [15] 
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proposed a joint model that consists of two three-state CTMCs, and applied it to two 
neuropsychological markers in AD to understand the transition probability among disease 
severity levels.  Yu et al. [16] illustrated a similar joint model with two two-state CTMCs in a 
stress study, and explored the association between mothers’ stress level and children's illness 
status.  However, not many Markov Chain studies in the literature modeled the longitudinal 
process as a covariate and integrated it to the outcome of interest.   
One of the few Markov Chain studies that examined the longitudinal process as a 
covariate was found in a dissertation work.  Ho [17] modeled the longitudinal DNA-damage 
process as a Discrete Time Markov Chain (DTMC) to predict the occurrence of lung cancer in a 
case-control study.  This method used the information that is repeatedly measured from genetic 
testing and modeled them as a DTMC with transition probabilities estimated, and the estimated 
transition probabilities are then applied into a logistic regression to estimate the odds of 
developing lung cancer.  This concept was later extended to the CTMC that modeled 
longitudinal intracranial pressure (ICP) as a CTMC with the transition rates as covariates in a 
logistic regression to predict the status of patients with traumatic brain injuries [18].  However, 
to our knowledge, no studies have modeled longitudinal process as covariates through Markov 
Chain and linked to the time-to-event outcome.  
Therefore, in this paper, to provide a solution to the condition when individual 
heterogeneity was observed in a longitudinal process with a time-to-event outcome, we propose a 
joint model of a Markov Chain and a Weibull regression that describes a longitudinal process as 
CTMC and treats the generated transition rates as covariates in the Weibull regression model to 
predict a survival event occurring after the longitudinal process.  We will apply this model to a 
completed patient-reported outcome (PRO) study using the MD Anderson Symptom Inventory 
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(MDASI) [19] for lung cancer patients who received chemotherapy at the MD Anderson Cancer 
Center.  In this application, the repeated patient-reported symptom severity during the 
chemotherapy periods are handled as a CTMC and are used to evaluate its association with post-
treatment overall survival in the Weibull regression model. 
The remainder of this paper is organized as follows: In Section 2, we describe the 
proposed joint model including the likelihood function and its estimation procedures.  Section 3 
provides validation of the estimating procedure through simulation.  Application of the proposed 
model to the real world PRO research is demonstrated in Section 4.  In the last section, we 
discuss the advantages and limitations of the proposed model. 
  
2.2 Methods 
We develop a joint model which consists of a combination of a time-to-event model and 
a two-state CTMC.  Through this joint model, we are able to consider simultaneously the effect 
of baseline covariates on the time-to-event outcome as well as on the longitudinal covariate 
process that is dependent on other covariates and is associated with the time-to-event outcome. 
2.2.1 The Joint Weibull Model and Two-state CTMC Model with Covariates 
In the CTMC submodel, let ܶ be a time-to-event outcome, and ܼሺݐሻ be a homogeneous 
CTMC with a state space ܵ ൌ ሼ1, 2ሽ characterized by the transition rates ߣ and ߤ.  The transition 
rates matrix can then be defined as  
ܳ ൌ ൤െߣ ߣߤ െߤ൨ 
where ߣ represents the transition rate from State 1 to State 2, while ߤ represents the transition 
rate from State 2 to State 1.    
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In the Weibull submodel, let ܺ be a vector of covariates directly related to the time-to-
event outcome ܶ.  Also, vector  ࢜ is the vector of covariates related to ܶ through the transition 
rate ߣ, and vector ࢝ is the vector of covariates related to ܶ through the transition rate ߤ.  The 
survival function of ܶ can then be expressed as  
ܵሺݐሻ ൌ ݁ݔ ݌ሺെሺࢄᇱࢼ ൅ ܾଵߣ ൅ ܾଶߤሻݐఊሻ ൌ ݁ݔ ݌൫െ൫ࢄᇱࢼ ൅ ܾଵe࢜ᇲࢍ ൅ ܾଶe࢝ᇲࢎ൯ݐఊ൯ 
where ࢼ ൌ ൫ߚ଴, ߚଵ,⋯ , ߚ௣൯் is the effect of the baseline covariates vector ࢄ on the outcome ܶ.  ߛ 
is the Weibull shape parameter.  ܾଵand ܾଶ are the overall multiplicative effects of the transition 
rates ߣ and ߤ, respectively, on the survival outcome.  Because of the stationary assumption of 
CTMC, the probability of moving from one state to another in a unit time ݐ is the same at any 
time point.  Note that, because ߣ and ߤ are both positive, we rewrite the transition rates as an 
exponential form and allow the regression expression on each form’s exponent.  Therefore, ࢍ is 
the effect of the covariate vector ࢜ on the transition rate ߣ, and ࢎ is the effect of the covariate 
vector ࢝ on the transition rate ߤ.   
2.2.1.1 Interpretation of the transition rates 
The association of the covariates ߣ and ߤ with the outcome ܶ can be interpreted as 
follows: For each unit increment in the transition rate ߣ, the outcome ܶ is expected to change by 
a multiplicity of ݁௕భ, while holding other covariates constant.  Similarly, for each unit increment 
in the transition rate ߤ, the outcome ܶ is expected to change by a multiplicity of ݁௕మ, while other 
covariates remain as constants.  The interpretation of other parameters including ߚ, ݒ, and ݓ is 
provided in Section 2.4.3.2 and Section 2.4.3.3. 
2.2.2 The Likelihood Function of the Proposed Joint Model 
The joint likelihood function for the longitudinal covariate process and the Weibull 
outcome model for n subjects can be written as 
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ܼሺݏሻ is a family of random variables that describes the state of a continuous process at time ݏ 
with state space ܵ ൌ ሼ1, 2ሽ.  ௔ܲ௕ሺሻ is the probability of transition from ܽ to ܾ for a fixed time 
interval, which can be explicitly expressed in transition rates ߣ and ߤ.  Also, ࢗ௜ ൌ ሺߣ௜, ߤ௜ሻ ൌ
ሺ݁࢝ᇲࢎ, ݁࢜ᇲࢍሻ is the vector of the transition rates.  Note that the set of covariates ሺ࢜,࢝ሻ can be 
identical or different from the vector ࢄ.  Besides, ܭ is the state that specifies in state space ܵ, and  
ܬ௜ is the number of transitions measured in the CTMC process for subject i, and ߜ௜ is the indicator 
of occurrence of a survival event. 
2.2.3 Estimation and Initial Values for Iterative Procedures 
The maximum likelihood method was used to maximize the formula in Section 2.2.2 with 
respect to ࢼ, ࢈, ࢎ, and ࢍ in a one-stage procedure.  This is a nonlinear optimization problem 
where there is no closed-form solution for parameter estimators.  Newton-Raphson optimization 
was used in the study to maximize the likelihood and obtain the estimators of interest.  It did not 
require any calculation of derivatives for each parameter, so it was adequate for problems with 
non-smooth functions and applicable to most statistical software.  For analyses and simulation in 
the study, PROC NLMIXED in SAS 9.4 (SAS Institute, Cary NC) was applied. 
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To speed up the computational time and increase the likelihood of reaching a global 
maximum, we selected the initial values for numerical estimation by implementing  the 
following two-step algorithm: 
1. A usual two-state CTMC model with covariate sets ࢜ and ࢝ was fit to find the parameter 
value sets ࢍ and ࢎ.  At this step, time-to-event outcome ܶ and baseline characteristics ܺ 
were ignored.   
2. Following Step 1, the transition rates ߣ and ߤ were calculated with covariates ࢜ and ࢝ 
and parameter values ࢍ and ࢎ.  The transition rates were then incorporated to the Weibull 
Model with survival outcome ܶ to obtain the estimators for ࢼ, ࢈, and ߛ.  Once this model 
was fitted, the initial values for all parameters were ready for the joint model. 
 
2.3 Simulation and Validation of the estimation procedure 
2.3.1 Description of the Simulation Study 
To validate the estimation procedure of the joint models, we also conducted simulations 
to examine our proposed model.  The “true” parameters in this simulation study were obtained 
from the application of the proposed model to PRO studies.  The data simulation procedure was 
a two-step process (see Figure 2.1). The covariates were first simulated following each variable’s 
specified distribution.  The transition rates and the Weibull distribution dependent on these rates 
were then simulated accordingly. A complete description and a flowchart of the simulation 
mechanism are as follows: 
2.3.1.1 Simulation of covariates 
The goal of this study is to develop prognostic models to predict survival in patients with 
cancer.  Therefore, the type of covariates and the distributions of chosen for the simulation study 
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should mimic those in PRO studies.  For simplicity, we simulated a few covariates that might be 
encountered in real-world data. 
Figure 2.1. Simulation procedure of Markov Chain and time-to-event outcome. 
 
1. Covariates in Markov Chain:  Two covariates, one continuous (ݒଵ) and one binary (ݒଶ) 
were simulated as predictors directly associated with the transition rate ߣ.  ݒଵ followed a 
normal distribution, and ݒଶ followed a Bernoulli distribution.  Similarly, one continuous 
variable (ݓଵ) and one binary variable (ݓଶ) were simulated for the transition rate ߤ.   
2. Baseline covariates in the survival model:  In the Weibull model, we simulated two 
covariates (one continuous (ݔଵ) and one binary (ݔଶ)) to explain the effect of baseline 
characteristics on the survival outcome.  ݔଵ followed a normal distribution, and ݔଶ 
followed a Bernoulli distribution.    
2.3.1.2 Simulation of Markov chain 
The simulation for a two-state CTMC required fixed transition rates ߣ and ߤ for each 
subject.  The transition rates were calculated based on the covariate sets ࢜ ൌ ሺݒଵ, ݒଶሻ and ࢝ ൌ
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ሺݓଵ, ݓଶሻ generated from the procedures presented in Section 2.3.1.1.  Once ߣ and ߤ were 
obtained, the CTMC was simulated, and its states were observed at prespecified time points for 
each subject in the study [20]. 
2.3.1.3 Simulation of time-to-event outcome  
The survival outcome was simulated based on the covariates ݔଵ, ݔଶ, ߣ, and ߤ obtained 
from the previous steps.  The Weibull distribution type of survival time ܶ can be expressed as 
[21] 
ܶ ൌ ߙିଵሾ݄଴ ൈ exp	ሺെࢼ′ࢄሻሿଵ/ఊ 
where ݄଴ is a pre-specified baseline hazard; ߙ is the scale parameter; and ߛ is the shape 
parameter.  The dependency of covariates has been adjusted through log-linear transformation, 
indicating the survival time ܶ followed the Weibull distribution with varying scale parameter 
ߙሺݔሻ ൌ ߙ ∙ exp	ሺࢼ′ࢄሻ.  The shape parameter ߛ was set at 1.2. 
2.3.2 Implementation and simulation results 
 We examined our proposed joint model when: (i) the transition rates were associated with 
the survival outcome, and (ii) the transition rates did not affect the survival outcome.  In both 
scenarios, we ran 1,000 times of simulations with 150 subjects in the simulated data, yet we 
burned-in the first ten times of the simulated data.  The length of the Markov Chain was set as 30 
weeks.  
In Scenario (i), when the transition rates were associated with the main outcome (i.e. 
ܾଵ ് 0, ܾଶ ് 0), the proposed joint model performed well in both accuracy and precision (see 
Table 2.1).  Except that the estimate of the transition rate ߤ had a slightly higher bias, the 
estimates of the parameter were close to the true value.  The coverage probability for each 
parameter ranged from 83% to 96%, which was acceptable.  Besides, the standard deviation (SD) 
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of the estimates across all simulation runs were close to the average of the square root of 
estimated variance (SE) for each run, indicating the number of simulation runs was appropriate.   
 
Table 2.5 Simulation results of the proposed model (N=150 subjects, R=1,000, Weeks=30) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
Intercept ߚ଴ ൌ2.5 2.31 -0.19 1.88 2.15 0.85 ݔଵ (binary) ߚଵ ൌ0.3 0.30 0.00 0.19 0.19 0.94 ݔଶ (continuous) ߚଶ ൌ1 1.00 0.00 0.09 0.09 0.93 ߛ (Weibull shape) ߛ ൌ1.1 1.13 0.03 0.08 0.08 0.94 
ߣ	  ܾଵ ൌ-0.5 -0.70 -0.20 0.99 0.90 0.96 
    ݓ଴ (intercept) ܿ଴ ൌ-0.7 -0.81 -0.11 0.11 0.11 0.83 
    ݓଵ (binary) ܿଵ ൌ0.1 0.09 -0.01 0.10 0.09 0.94 
    ݓଶ (continuous) ܿଶ ൌ0.3 0.27 -0.03 0.07 0.06 0.91 
ߤ	  ܾଶ ൌ0.6 1.26 0.66 4.28 4.98 0.86 
    ݒ଴ (intercept) ݀଴ ൌ-0.8 -0.85 -0.05 0.11 0.11 0.85 
    ݒଵ (binary) ݀ଵ ൌ-0.15 -0.14 0.01 0.09 0.09 0.87 
    ݒଶ (continuous) ݀ଶ ൌ-0.2 -0.19 0.01 0.40 0.41 0.86 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
 
Moreover, to evaluate the performance of the proposed model in the condition of null 
transition rates effect on the outcome (i.e. Scenario (ii)), we set ܾଵ ൌ 0 and ܾଶ ൌ 0 when we 
simulated the survival outcome.  Table 2.2 shows the result of Scenario (ii).  Similar to Scenario 
(i), the estimates were close to the true parameters except for the transition rate ߤ, and SD was 
also close to SE at each parameter while the coverage probability ranged from 0.85 to 0.96.  As a 
result, the proposed model could become a regular Weibull model when there was no effect from 
the transition rates. 
We also tested the simulated data in each scenario in the regular Weibull model for 
model performance.  When the transition rates exert no effect on the survival outcome (Scenario 
(ii)), the regular Weibull model should perform better as compared to the model performance in 
Scenario (i).  The bias in Scenario (i) should be larger, and the coverage probability would be 
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lower.  Table 2.3 shows the summary of the Weibull model performance in each scenario.  
Overall, the model performance in Scenario (i) included higher bias, especially in the intercept 
with a lower coverage probability at 88%.  However, the rest of the parameters,  ݔଵ, ݔଶ, and ߛ, 
had the same performance in each scenario. 
 
Table 6.2 Simulation results using the proposed model to analyze data with no Markov 
Chain effect included on the survival outcome (N=150 subjects, R=1,000, Weeks=30) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
Intercept ߚ଴ ൌ2.5 2.19 -0.31 1.89 2.23 0.85 ݔଵ (binary) ߚଵ ൌ0.3 0.30 0.00 0.20 0.19 0.94 ݔଶ (continuous) ߚଶ ൌ1 1.00 0.00 0.09 0.09 0.93 ߛ (Weibull shape) ߛ ൌ1.1 1.13 0.03 0.08 0.08 0.94 
ߣ	  ܾଵ ൌ 0 -0.01 -0.01 0.98 0.91 0.96 
    ݓ଴ (intercept) ܿ଴ ൌ-0.7 -0.81 -0.11 0.11 0.11 0.84 
    ݓଵ (binary) ܿଵ ൌ0.1 0.09 -0.01 0.10 0.09 0.93 
    ݓଶ (continuous) ܿଶ ൌ0.3 0.27 -0.03 0.07 0.06 0.91 
ߤ	  ܾଶ ൌ 0 0.76 -0.76 4.33 5.18 0.86 
    ݒ଴ (intercept) ݀଴ ൌ-0.8 -0.85 -0.05 0.11 0.11 0.85 
    ݒଵ (binary) ݀ଵ ൌ-0.15 -0.14 0.01 0.09 0.09 0.86 
    ݒଶ (continuous) ݀ଶ ൌ-0.2 -0.19 0.01 0.41 0.42 0.86 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
 
Table 2.7 Simulation results of Weibull model in two scenarios (N=150 subjects, R=1,000, 
Weeks=30) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
Scenario (i). Markov Chain effect on survival outcome. (࢈૚ ് ૙, ࢈૛ ് ૙) 
Intercept ߚ଴ ൌ2.5 2.38 -0.12 0.17 0.16 0.88 ݔଵ (binary) ߚଵ ൌ0.3 0.30 0.00 0.19 0.19 0.95 ݔଶ (continuous) ߚଶ ൌ1 1.01 0.01 0.09 0.09 0.94 ߛ (Weibull shape) ߛ ൌ1.1 1.11 0.00 0.08 0.08 0.95 
Scenario (ii). No Markov Chain effect on survival outcome. (࢈૚ ൌ ૙, ࢈૛ ൌ ૙) 
Intercept ߚ଴ ൌ2.5 2.49 -0.01 0.17 0.16 0.94 ݔଵ (binary) ߚଵ ൌ0.3 0.30 0.00 0.19 0.19 0.95 ݔଶ (continuous) ߚଶ ൌ1 1.01 0.01 0.09 0.09 0.93 ߛ (Weibull shape) ߛ ൌ1.1 1.11 0.01 0.08 0.08 0.95 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
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2.4 Application 
2.4.1 Study Population and Description of the Proposed Joint Model 
We also applied the proposed model to a study called NSCLC study in this paper, which 
includes non-small cell lung cancer (NSCLC) patients recruited between 2004-2009 at The 
University of Texas MD Anderson Cancer Center (MDACC) thoracic medical oncology clinic.  
The patients were at least 18 years old and they all had with late-stage IIIB and IV NSCLC.  The 
inclusion criteria of the study included English speaking ability, performance score between 0-2, 
and first-line chemotherapy scheduled.  A total of 94 patients were eligible for the study.  The 
PROs were collected using the MD Anderson Symptom Inventory (MDASI) before and after 
chemotherapy treatment cycles. Two additional common symptom items in NSCLC, coughing 
and constipation, were also collected through MDASI.  The patients were scheduled to complete 
the MDASI assessment at baseline, chemotherapy treatment (weekly), and post-treatment 
follow-up.  The survival data were then collected from the MDACC medical record system or 
followed up by the research coordinators.   
In a previous publication [22] using the NSCLC data, it was stated that baseline coughing 
score (a binary variable using score 4 as cut-point) could predict the overall survival with a 
hazard ratio (HR) at 8.69 (95% CI: 3.53 - 21.38) while adjusting for patients’ performance score 
and race in the model.  Fatigue and shortness of breath were also found associated with the 
overall survival in the study.  The symptoms change (treated as continuous variables) between 
baseline and at the end of first chemotherapy cycle showed the HR was 2.41 (95% CI: 1.32 – 
4.37) and 2.30 (95% CI: 1.19 – 4.43) for fatigue and shortness of breath, respectively.   
The motivation of this application is to fully utilize the longitudinal PRO data in the 
survival analysis when individual heterogeneity in longitudinal PRO symptoms is observed.  Our 
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proposed joint model with Markov Chain and the Weibull model may provide a different 
solution to this type of study by using PROs at baseline and complete chemotherapy cycles to 
predict survival outcome happened after the treatment period.   
2.4.1.1 Markov Chain Submodel 
 We used fatigue in this application because the previous study showed that changes in 
fatigue score were associated with overall survival [22].  We dichotomized the MDASI-fatigue 
scoring system (score 0 - 10) into a binary variable using a cut-point at 4, where score greater 
than or equal to 4 indicated symptoms at the moderate/severe state, and score less than 4 
indicated symptoms at the none/mild state [23, 24].  For each symptom, we excluded subjects 
who had never reported a symptom change across the two states (moderate/severe vs. 
none/mild).  The transition from none/mild to moderate/severe was called worsening rate 
represented by ߣ, and the transition from moderate/severe to none/mild was called as improving 
rate, and represented by ߤ.  The longitudinal fatigue data were also transformed into the 
transition types of data to fit the Markov Chain submodel.   
2.4.1.2 Main outcome model (Weibull model) 
 The post-treatment survival is the outcome in the Weibull regression model.  It is 
calculated from the end of treatment date to the date of death, or the last date followed up.  The 
Weibull regression model included individual transition rates (ߣ and ߤ must be included), 
demographic variables, and some clinical variables.   
2.4.2 Model selection 
During the model selection process, both Markov Chain submodel and the Weibull 
submodel could adjust with demographic variables and clinical variables.  Demographic 
variables included age, gender (female vs. male), race (white vs. non-white), marital status 
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(currently married vs. not married), and job (currently employed vs. not employed).  Clinical 
variables included baseline cancer stage (IV vs. III), previous treatment (Yes/No), solid tumor 
(Yes/No), Charlson Comorbidity Index (CCI, 1 or higher vs. 0), Eastern Cooperative Oncology 
Group Performance Status (ECOG-PS, 2 vs 0-1), ever smoke (Yes/No), and length of smoking 
before study.   
For the model selection process, we applied a backward selection strategy in two steps: 
Step 1. Model selection in the Markov Chain submodel.  We considered all variables 
(demographic or clinical) in the transition rates and selected an optimal model when only 
transition rates were included as covariates in the Weibull model.   
Step 2. Model selection in the Weibull model.  After Step 1, we conducted another model 
selection process in the Weibull model which included both demographic variables and clinical 
variables.  However, the significance of covariates in transition rates might change after the 
covariates were incorporated in the Weibull model. 
2.4.3 Results of the joint model 
We excluded one patient who had no changes in fatigue score between the two states 
(none/mild vs. moderate/severe), and we also excluded patients who had missing data in any of 
the demographic variables and clinical variables during the model selection.  As a result, there 
were 81 patients used in the analysis.  70% of these patients died in the study, with a median 
post-treatment survival time of 43 weeks.  Besides, the average treatment period was 17.2 weeks, 
ranging from 6 to 42 weeks.   
Table 2.4 shows the results of the optimal model of the joint Markov Chain and Weibull 
model.   Worsening rate was associated with covariates such as age, previous surgery, and 
ECOG-PS, while improving rate was associated with the length of smoking, previous treatment, 
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and CCI.  The Weibull submodel included both transition rates adjusted by other covariates like 
age, cancer stage, race, gender, previous treatment, and ECOG-PS.  The worsening rate ߣ 
showed a negative association with the survival time, but the improving rate ߤ showed a positive 
association with on the survival outcome.   
2.4.3.1 Interpretation of the transition rate effect on the outcome 
 For a unit increment in the worsening rate (ߣ), meaning the time from none/mild to 
moderate/severe was shorter, or the patient reported more often in the moderate/severe state 
during the chemotherapy cycles, the overall survival time was expected to change by a 
multiplicity of expሺെ0.04ሻ ൌ 0.96 while holding other covariates as constants.  This indicated a 
4% decrease for a unit increment in the worsening rate when the time unit in the Markov Chain 
was a week (7 days).  On the other hand, a unit increase in improving rate (ߤ), meaning a patient 
reported more frequently in the none/mild state during treatment cycles, the survival time would 
change by a multiplicity of expሺ2.19ሻ ൌ 8.94 while adjusting with other covariates.  Even 
though both transition rates were not statistically significant at a 0.05 level, the directions of 
estimates for transition rates were estimated as expected.  A higher worsening rate shortened the 
survival time, and a higher improving rate would prolong the survival time.  We expect the 
proposed model to perform better in estimation when the length of Markov Chain (longitudinal 
PRO observations) is longer.  Both transition rates followed the proportional hazard assumption. 
2.4.3.2 Interpretation of covariates to the outcome 
  When interpreting the effect of covariates on the survival outcome, special attention was 
paid because some covariates were included in both the Weibull submodel and in the Markov 
Chain submodel.  For example, age was selected in both the Weibull model and the worsening 
rate in the Markov Chain model.  Since age was standardized before it was used in the model, 
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when a unit of a standard deviation increase on age (i.e. 9.1 years), the survival time would 
change by a multiplicity of expሺ0.33 ൅ ሺെ0.04 ൈ exp	ሺെ0.70 ൅ 0.001 ൈ 1ሻሻሻ ൌ 1.36 when 
holding other covariates as constants.   
 For the covariates selected only for the Weibull submodel, the interpretation is the same 
as that for any standard Weibull model.  For instance, female patients (variable gender, using 
male as the reference group) had 46% (expሺ0.48ሻ ൌ 1.62) longer survival time than male 
patients while controlling other variables as constants. 
 
Table 2.8 Result of the joint Markov Chain and Weibull model applied to the NSCLC 
study 
Covariates in the joint model Estimate SE* Pr > |t| 
Weibull submodel 
Intercept 4.84 1.05 < 0.01 
Agea 0.33 0.22 0.14 
Stageb -2.09 0.61 < 0.01 
Racec -0.83 0.55 0.14 
Genderd 0.48 0.40 0.24 
Previous Treatmente -0.80 0.59 0.17 
ECOG-PSf 0.58 0.43 0.17 
Weibull shape 0.89 0.12 < 0.01 
ߣ  -0.04 0.51 0.93 
ߤ  2.19 1.62 0.18 
Markov Chain submodel for transition rate ࣅ 
ݓ଴ (intercept) -0.70 0.15 < 0.01 
Agea 0.001 0.12 0.92 
Previous Surgeryg 1.29 0.32 < 0.01 
ECOG-PSf 0.30 0.18 0.10 
Markov Chain submodel for transition rate ࣆ 
ݒ଴ (intercept) -0.44 0.20 0.03 
Smoking lengthh 0.08 0.09 0.42 
Previous Treatmente 0.43 0.19 0.03 
CCIi -0.52 0.20 0.01 
*SE: Standard error, aper 9.1 years, bstage IV vs. III, cwhite vs. non-white, 
dfemale vs. male, eYes vs. No, f2 vs. 0-1, gYes vs. No, hper 7.9 years, i1+ vs. 0 
 
2.4.3.3 Interpretation of covariates to the transition rates 
34 
 
 In order to account for the baseline covariates effect on the longitudinal PRO trend in the 
Markov Chain model (i.e., the transition rates), our proposed model allows covariates to be put 
into the Markov Chain submodel.  For example, the dichotomized Charlson Comorbidity Index 
(CCI) was selected in the improving rate with a negative sign (est ൌ െ0.52), indicating a lower 
improving rate (expሺെ0.52ሻ ൌ 0.59) would be expected when the CCI was larger than and equal 
to 1.  This association is expected because a higher CCI means the worse condition on the patient 
and then reduce the improving rate.    
 
2.5 Discussion 
In previous sections, we have developed a new methodology that can incorporate 
longitudinal covariates in a survival framework.  We proposed a joint Markov Chain and 
Weibull model that could adjust a longitudinal covariate in the Weibull model when individual 
heterogeneity is found in the longitudinal covariate.  Our simulation results have shown the 
model estimation procedure is valid and model performance is good in both accuracy and 
precision.  We also applied the proposed method in a PRO study that examined longitudinal PRO 
during the treatment period with the post-treatment overall survival of lung cancer patients.  
Even though the transition rates did not show statistical significance, the direction of estimates 
for transition rates and other covariates aligned with our expectations. 
When comparing our proposed joint modeling to the time-dependent covariate approach 
in survival model or another joint modeling approach that combine a longitudinal model with a 
survival model, our proposed approach has a fundamental difference in ability to model the data 
we analyzed from those other approaches.  In our proposed approach, we modeled the 
longitudinal process (e.g., longitudinal PRO during the treatment cycles) using a CTMC, and 
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included the generated transition rates as covariates similar to other baseline covariates.  The 
survival event would only happen after the longitudinal process, so we use the post-treatment 
survival time (calculated from time of treatment completion to the survival event) in the 
application.  The usage of the transition rates, therefore, will behave like other baseline 
covariates, and these transition rates can perform as predictors to the survival time.  Other joint 
modeling approaches or time-dependent survival model are not appropriate in analyzing this type 
of dataset because they usually require a longer longitudinal pattern of data and for it continue 
until the survival event happened. 
 There are some advantages in this joint Markov Chain and Weibull model.  First, 
modeling longitudinal data in Markov Chain can reduce the dimension of covariates in the main 
effect model.  By using two transition rates in the Weibull submodel to explain the longitudinal 
effect of the covariate on survival outcome, we are able to interpret the longitudinal trend at the 
individual level.  Second, CTMC tends to be more suitable for clinical data since they are often 
collected at unequal time intervals due to patients’ missing appointments or scheduling 
problems.  Third, the Weibull model is a common parametric approach in the survival analysis 
that can explain the association between a factor and survival outcome.  The nature of this 
parametric approach also makes it easily to apply the joint model approach using popular 
statistical software such as SAS or R by outlining the likelihood of the model.  Additionally, to 
our best knowledge, this is the first time that a method integrates CTMC with a Weibull model.   
One of the disadvantages of this method is that we may lose some information from the 
longitudinal covariates when dichotomizing a continuous score into a binary variable.  However, 
this particular disadvantage could also be a benefit for PRO research.  For instance, some PRO 
instruments [19, 25-27] scoring can be considered as an ordinal or a continuous variable, but it is 
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always a challenge to interpret a unit difference in the original scoring system.  Therefore, in the 
NSCLC study, we transformed the original score from 0 to 10 into a two-level variable based on 
previous research [24], leading this method to be more clinically meaningful.    
Besides, the identifiability problem in Markov Chain could be a challenge when the joint 
model method is applied to real-world data.  If the longitudinal trends (transition between the 
two states in Markov Chain) are the same in individuals and the number of covariates adjusted is 
limited, the identifiability problem may cause estimation difficulty and incompleteness in model 
optimization (e.g., Newton-Raphson optimization).   
Moreover, Like other joint model approaches, initial values are important for model 
optimization.  In the simulation process to validate our methodology, the estimates of parameter 
were the same when using our initial value approach (see Section 2.2.3) or setting initial values 
as non-informative value as 1.  These identical results indicate the proposed computational 
approach is robust to the specification of initial values.  The optimization (i.e., Newton-Raphson 
optimization) was able to find the global maximum of the likelihood function. 
Furthermore, there are other limitations to this model.  The length of Markov Chain is 
also crucial to the model performance.  Section 2.3.2 showed the simulation result in 30 unit (in 
weeks) of time.  We also tested the model performance in a longer length of Markov Chains and 
observed smaller bias and better coverage probability.  Besides, in the application, we excluded 
one subject reported no change in fatigue between none/mild and moderate/severe level.  The 
result of our approach may be biased if the proportion of this group of patients is large.   
In conclusion, we built a joint two-state CTMC model and a Weibull model to the 
situation when a longitudinal covariate effect exists on time-to-event types of outcome.  Our 
proposed method is especially useful when individual heterogeneity is observed in longitudinal 
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covariates.  The model is appropriate for clinical data collection setting, and it is easy to 
implement using standard statistical software.  Our method provides a more flexible alternative 
to modeling PRO data when patients’ longitudinal measurements show distinct trajectories. 
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The Relationship Between the Longitudinal Covariates During the Treatment Period as a 
Markov Chain and The Post-Treatment Survival in Cox Regression 
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3.1 Background 
Patient-reported outcome (PRO) has become a popular mechanism for measuring patient 
experience in medical research when more and more clinical trials use it as their primary 
outcome or exploratory outcome [1-3].  Government agencies such as US Food and Drug 
Administration (FDA) and the European Medicine Agency (EMA) have provided guidelines for 
PRO research and specified the considerations of PRO application [4-7].  So far, PRO has been 
linked to survival outcomes and research has shown that PRO monitoring during chemotherapy 
can improve survival in patients with advanced cancer diagnosis [8].  Also, baseline PRO has 
been used to predict survival outcome in previous studies [9, 10].  Nevertheless, when PRO 
contains repeated measurements, the effect of longitudinal PRO on the survival outcome 
becomes complex, and its relevant statistical models need more sophisticated considerations.  
Due to the nature of PRO that collects clinical response directly from the patients and can be 
varied across patients, it is common to observe distinct trajectories of PRO on each patient in a 
longitudinal study.  However, current methods, such as a linear mixed model approach in joint 
modeling [11], are not able to account for distinct trajectories in individuals.  Therefore, in this 
paper, we propose a joint approach that utilizes the transition rates of a Continuous-Time 
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Markov Chain (CTMC) generated from longitudinally observed PROs during the treatment 
period as covariates in a Cox Proportional Hazard Regression (Cox PH model) [12] to evaluate 
the effect of longitudinal PRO on post-treatment survival.    
Longitudinal PRO Analysis 
 Longitudinal PROs can provide more symptom and health-related quality of life 
(HRQoL) information related to the disease and treatment involved.  A comprehensive design 
collecting longitudinal PRO data at baseline, treatment visits (weekly or bi-weekly), and post-
treatment follow-up (bi-weekly, monthly, or every six months) [13].  Therefore, PRO 
instruments can measure symptom change over the whole study period, provide detailed 
information on the differences before, during, and after treatment, and capture variation of 
symptoms.  The trajectory of longitudinal PRO may not always be linear.  In fact, in most of the 
observational studies on cancer with chemotherapy [14, 15], a weekly measured PRO during the 
chemotherapy cycles tends to show a non-linear pattern (waves).  This type of non-linear data 
can actually indicate whether a symptom is changed by the influence of the disease and/or by the 
effectiveness/burden of a treatment.      
Longitudinal PROs as Outcomes  
There are many approaches to analyzing longitudinal PROs, and most of them consider 
longitudinal PROs as outcome variables.  Lin et al. [16], for example, used a Linear Mixed-effect 
Model (LMM) to analyze the longitudinal HRQoL data from patients who had lumbar spine 
surgery in Taiwan.  They found neurological functions, sleep quality, and depressive symptoms 
were the key factors affecting quality of life.  In fact, LMM has been widely used in longitudinal 
PRO research because the model accounts for within-subject correlation, random data 
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missingness, and is easily interpreted.  For more information, Fairclough has described how to 
analyze a longitudinal PRO as an outcome [17]. 
Another approach to analyzing longitudinal PROs is to transform longitudinal 
information into a one-dimensional variable and analyze it using regular models depending on 
the type of the transformed variable.  For example, Shi et al. [18] transformed longitudinal PROs 
into binary or ordinal variables using Group-Based Trajectory Modeling (GBTM), and then 
treated these variables as outcomes in an (ordinal) logistic regression.   Compared with Lin et 
al.’s approach [16] which assumed the longitudinal PROs followed a general linear trend, Shi et 
al.’s approach was based on the assumption that the subjects had different patterns of 
longitudinal PROs. 
PROs as Covariates to Survival Outcome 
 A number of other studies also treated PROs as covariates and investigated the 
association between PROs and outcomes: Quinten et al. [19] suggested patients-reported 
symptoms (measured by EORTC-QLQ-C30) plus clinical rating (CTCAE) could more 
accurately predict overall survival.  Also, Armstrong et al. [9] linked the PROs (using both 
EORTC-QLQ-C30/BN20 and MDASI-BT) to examine the progression-free survival (PFS) and 
overall survival (OS) in patients with brain tumors.  They found that higher symptom burden on 
patients had a higher risk of OS and PFS, yet a higher QoL score was associated with a lower 
risk of OS and PFS.  In addition, Wang et al. [10] found baseline coughing and symptom 
worsening from baseline to the end of the first chemotherapy cycle on fatigue and shortness of 
breath (measured by MD Anderson Symptom Inventory, MDASI) increased the risk of death in a 
study on late-stage non-small cell lung cancer patients.  However, most studies conducted so far 
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only used PROs at a specific time point as covariates in their models.  None of them has directly 
applied longitudinal PROs as covariates in the model to predict survival outcomes.   
Markov Chain Model 
One useful statistical approach to modeling a longitudinal covariate process is Markov 
Chain, and it has already been used to describe the progression of Alzheimer's disease [20, 21] 
and Parkinson's disease [22, 23] when the diseases' process follows the Markov Property, in 
which the state of the future events only depends on the current state, not any past state.  
Previous studies have included a Markov Chain as covariates in their models for cross-sectional 
outcomes.  Ho [24] modeled a longitudinal DNA-damage process as a Discrete Time Markov 
Chain (DTMC) to predict the occurrence of lung cancer in a case-control study.  Rubin et al. [25] 
later extended this concept to a Continuous Time Markov Chain (CTMC) and modeled 
longitudinal intracranial pressure (ICP) with CTMC as covariates in a logistic regression model 
to predict the future status of patients with traumatic brain injuries.   
In this paper, we developed a joint approach that uses CTMC as a longitudinal covariate 
to predict a survival type of outcome that happens after the longitudinal process in a two-stage 
procedure.  The model description, the likelihood function, and the estimation procedure are 
illustrated in Section 3.2.  Sections 3.3 shows the simulation results of the proposed method, 
while Section 3.4 shows an application on a study with head and neck cancer patients.  The 
advantages and challenges of the proposed method and conclusion of the study are presented in 
Section 3.5. 
 
3.2 Methods 
3.2.1 Continuous-Time Markov Chain 
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Ross [26] and Pinsky and Karlin [27] have illustrated Continuous-Time Markov Chain 
with detailed specification and methodology.  In this paper, we used the transition rates of a two-
state time-homogeneous CTMC as covariates into a Cox PH model.  For a CTMC, the transition 
probabilities can be determined by solving a system of differential equations.  When the number 
of the states is equal to 2, the explicit formulas of transition probabilities are as follows:  
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Where ௜ܲ௝ሺݐሻ is the transition probability from state ݅ to state ݆, ݅, ݆ ൌ 1,2.  ߣ is the transition rate 
from State 1 to State 2, and ߤ is the transition rate from State 2 to 1.  Given that there are N 
subjects in the study sample, the parameters ߣ and ߤ can be estimated using the maximum 
likelihood method.  The likelihood function can then be written as 
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where ݅ ൌ 1, 2,  
ܫ௜ሾܼሺݐሻሿ ൌ ൜1, ݂݅	ܼሺݐሻ ൌ ݅0, ݋ݐ݄݁ݎݓ݅ݏ݁  
and ܲሾܼሺ0ሻ ൌ ݅ሿ is the probability when the initial state is equal to ݅.  
In clinical studies, researchers are usually interested in studying the effect of different 
subject characteristics on a particular outcome.  To achieve this goal, in a Markov model, the 
dependency of covariates on the transition rates can be modeled through a log link:  
ߣሺݒሻ ൌ e࢜ᇲࢍ, and ߤሺݓሻ ൌ e࢝ᇲࢎ, where ࢍ represents a vector of coefficients for a covariate vector 
࢜, and ࢎ represents a vector of coefficients for a covariate vector ࢝.  Note that the vectors ࢜ and 
࢝ can be identical, completely different, or partially overlapped in their components. 
3.2.2 Cox Proportional Hazard Model (Cox PH Model) 
The Cox PH model has been widely used in clinical research because it is easy to 
interpret a survival type of outcome as a risk of disease.  Klein and Moeschberger [28] and 
Hosmer and Lemeshow [29] have described the model specification and estimation procedure of 
the Cox PH model in detail.  Here, we briefly outline the components of the Cox PH model: 
Let ܶ denote the time to the event, and ߜ be the event indicator (ߜ ൌ 1 if the event 
occurs, and ߜ ൌ 0 if the event is right-censored).  ࢆ is a vector of baseline covariates which may 
affect the survival distribution of T.  The Cox PH model can be expressed as  
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݄ሺݐ|ࢆሻ ൌ ݄଴ሺݐሻexp	ሺࢼ′ࢆሻ 
where ݄ሺݐ|ܼሻ is the hazard at time ݐ given the covariate set ࢆ.  Also, ݄଴ሺݐሻ is the baseline hazard, 
and ࢼ is a vector of coefficients with respect to covariate set ࢆ.  Since the baseline hazard, ݄଴ሺݐሻ, 
is usually not the interest of a study, we can only estimate the covariate effect ࢼ through the 
partial likelihood method. The partial likelihood for the Cox PH model can be written as  
ܮሺߚሻ ൌෑ exp	ሺߚ′ܼ௜ሻ∑ exp	ሺߚ′ ௝ܼሻ௝∈ோሺ௧೔ሻ
஽
௜ୀଵ
 
where D represents the set of subjects when an event occurs, and ܴሺݐ௜ሻ is the set of subjects at 
risk at time ݐ௜.   
3.2.3 A Joint Two-Stage Approach 
We developed a prognostic modeling approach that is a combination of the Cox PH 
model with a two-state CTMC.  This approach allowed us to study the effect of a longitudinal 
covariate process on a survival type of outcome in terms of the hazard rate while controlling for 
other baseline covariates in both CTMC and the Cox PH model.   
Let ܶ be a time-to-event outcome, and Z(t) be a homogeneous CTMC with a state space 
ܵ ൌ ሼ1, 2ሽ characterized by the transition rates ߣ and ߤ.  ܺ is a vector directly related to the 
outcome ܶ.  ࢜ is a vector of covariates related to ܶ through the transition rate ߣ, and ࢝ is a 
vector of covariates related to ܶ through the transition rate ߤ.  The proposed joint approach can  
be expressed as  
݄ሺݐ|ܼሻ ൌ ݄଴ሺݐሻ expሺࢄᇱࢼ ൅ ࢗ࢏ᇱ࢈ሻ ൌ ݄଴ሺݐሻ expሺߚ଴ ൅ ߚଵ ଵܺ ൅ ⋯൅ ߚ௥ܺ௥ ൅ ܾଵߣ ൅ ܾଶߤሻ
ൌ ݄଴ሺݐሻexp	ሺߚ଴ ൅ ߚଵ ଵܺ ൅ ⋯൅ ߚ௥ܺ௥ ൅ ܾଵe࢜ᇲࢍ ൅ ܾଶe࢝ᇲࢎሻ 
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where ࢼ is the effect of the baseline covariate vector ࢄ on the outcome ܶ; ࢈ ൌ ሺܾଵ, ܾଶሻ is the 
effect of unobservable transition rates ࢗ࢏ ൌ ሺߣ௜, ߤ௜ሻ on the outcome, and ݄଴ሺݐሻ is the baseline 
hazard. 
We can acquire the estimates through the partial likelihood function.  For a study with N 
subjects, the partial likelihood of the proposed model can be expressed as  
ܮ൫ࢎ, ࢍ, ࢈, 	ࢼ൯ ൌ 
ෑ exp	ሺࢄ
ᇱࢼ ൅ ࢗ࢏ᇱ࢈ሻ
∑ exp	ሺࢄᇱࢼ ൅ ࢗ࢐ᇱ࢈ሻ௝∈ோሺ௧೔ሻ
஽
௜ୀଵ
ൌෑ exp	ሺࢄ
ᇱࢼ ൅ ܾଵe࢜ᇲࢍ ൅ ܾଶe࢝ᇲࢎሻ
∑ exp	ሺࢄᇱࢼ ൅ ܾଵe࢜ᇲࢍ ൅ ܾଶe࢝ᇲࢎሻ௝∈ோሺ௧೔ሻ
஽
௜ୀଵ
 
The notations here are the same as those in Section 3.2.1 and Section 3.2.2.   
In terms of the estimation procedure, we proposed a two-stage approach as follows: 
Stage 1. Estimate the unobservable transition rates ߣ and ߤ for a longitudinal covariate in 
a two-state CTMC.  First, we transformed a longitudinal covariate into transition type of data and 
applied the method that has been described in Section 3.2.1 and built the complete likelihood 
function.  With the log link function, we incorporated baseline covariates at each transition rate.  
After that, we used the maximum likelihood method to obtain the estimates of transition rates ߣ௜ 
and ߤ௜ at the individual level.   
Stage 2. Model the transition rates ߣ and ߤ as covariates in the Cox PH model.  We used 
the partial likelihood method to evaluate the covariate effects on the survival outcome including 
transition rates from Stage 1 and baseline covariates. 
3.2.4 Interpretation of Transition Rates 
Transition rates represented the speed of transition from one state to another in a 
longitudinal process.  Thus, evaluating the longitudinal covariate effect on the survival outcome 
and interpreting the transition rate correctly are important to this joint approach.  The association 
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of the transition rates ߣ and ߤ with the hazard rate at time ݐ, (݄ሺݐ|ܼሻ), can be interpreted as 
follows: For each unit increment in the transition rate ߣ, the hazard rate is expected to change by 
a multiplicity of ݁௕భ, while holding other covariates as constants.  Similarly, for each unit 
increment in the transition rate ߤ, the hazard rate is expected to change by a multiplicity of ݁௕మ, 
while other covariates are held as constant.   
 
3.3 Validation of the Estimation Procedure and Simulation 
3.3.1 Description of the Simulation Study 
We examined our proposed joint approach through simulations to validate our two-stage 
estimation procedure.  The parameter values were obtained from a PRO study [10] where limited 
covariates were adjusted in the model as described below.  Three majot steps were involved in 
the simulation procedure: simulation of covariates, simulation of Markov Chain, and simulation 
of time-to-event outcomes.  Figure 3.1 outlines the scheme of the simulation procedure. 
Figure 3.1. Simulation procedure of Markov Chain and time-to-event outcomes 
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3.3.1.1 Simulation of Covariates 
To reflect the situation of real-world data, we incorporated a set of covariates (a binary 
variable and a continuous variable) in both CTMC and the Cox PH model. 
In CTMC:  Two covariates, one continuous (ݒଵ) and one binary (ݒଶ) are simulated as 
predictors directly associated with the transition rate ߣ.  ݒଵ followed a Normal distribution, and 
ݒଶ followed a Bernoulli distribution.  Similarly, one continuous variable (ݓଵ) that followed a 
Normal distribution, and one binary variable (ݓଶ) that followed a Bernoulli distribution were 
simulated for the transition rate ߤ.   
In the Cox PH model:  Two covariates (one continuous type (ݔଵ) and one binary (ݔଶ) 
type) were also simulated to explain the effect of baseline characteristics on the survival 
outcome.  Similar to the setting of CTMC, ݔଵ followed a Normal distribution, and ݔଶ followed a 
Bernoulli distribution.    
3.3.1.2 Simulation of Markov Chain 
 Once the covariate sets ࢜ ൌ ሺݒଵ, ݒଶሻ and ࢝ ൌ ሺݓଵ,ݓଶሻ were generated from Section 
3.3.1.1, the individual transition rates ߣ௜ and ߤ௜ could be calculated through the log link function 
described in Section 3.2.1.  Next, CTMC was also simulated [30] based on individual transition 
rates.  As a result, each subject had their own simulated longitudinal observations with covariates 
adjusted. 
3.3.1.3 Simulation of Time-To-Event Outcome 
When the covariates ݔଵ, ݔଶ, ߣ, and ߤ were simulated and calculated from the previous 
steps, we then simulated survival outcome that followed a Weibull distribution.  Survival time ܶ 
which followed a Weibull distribution could be expressed as  
ܶ ൌ ሾ݄଴ ൈ exp	ሺെሺߚଵݔଵ ൅ ߚଶݔଶ ൅ ܾଵߣ ൅ ܾଶߤሻሻሿିଵ/ఊ 
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where ݄଴ is a pre-specified baseline hazard [29, 31], and ߛ is the shape parameter in the Weibull 
distribution.  The dependency of covariates had been adjusted through a log-linear 
transformation, so the scale parameter ߙሺݔሻ varied with covariates.  The shape parameter ߛ was 
set at 1.2 in the simulation. 
3.3.2 Implementation and Simulation Results 
Two simulation situations, Scenario (i) and Scenario (ii), were set up to examine the 
proposed joint approach.  In Scenario (i), we simulated the survival outcome when CTMC had 
an association with the survival outcome.  In contrast, we assumed a situation when there was no 
CTMC effect on the survival outcome in Scenario (ii), and set ܾଵ ൌ 0 and ܾଶ ൌ 0.  For each 
scenario, we ran 1,000 replicates, and for each of replicate, the length of CTMC was set at 10 
weeks with 150 subjects at each run.  
Table 3.1 shows the results of the proposed joint approach in Scenario (i) when ܾଵ ് 0, 
and ܾଶ ് 0.  The bias, difference between the estimate and true parameter value, of all 
parameters was small, and the coverage probabilities were appropriate and ranged from 0.90 to 
0.96.  The standard deviation (SD) of all the estimates across all simulation runs were close to 
the average of the square root of the estimated variance (SE) at each run for all parameters, 
indicating the number of simulation runs was appropriate.   
In Scenario (ii), when there was no transition effect on the survival outcomes (i.e. ܾଵ ൌ 0 
and ܾଶ ൌ 0), the proposed method detected the null transition rate effect in the simulated data 
(see Table 3.2).  The biases for all the parameters were small, and coverage probabilities were 
good with a range from 90% to 97%.  In terms of stability, SD and SE in Scenario (ii) were close 
to each other for all the parameters.  Therefore, the proposed approach became the regular Cox 
PH model without the covariate effect from the transition rates. 
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Table 3.1. Simulation results of the proposed model (N=150 subjects, R=1,000, weeks=10) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
ݔଵ (binary) ߚଵ = 0.03 0.30 0.00 0.21 0.21 0.95 ݔଶ (continuous) ߚଶ = -0.2 -0.21 -0.01 0.09 0.09 0.96 
ߣ	  ܾଵ = 0.6 0.74 0.14 0.84 0.70 0.93 
    ݓ଴ (intercept) ܿ଴ = -0.5 -0.62 -0.12 0.19 0.19 0.90 
    ݓଵ (binary) ܿଵ = 0.1 0.10 0.00 0.16 0.16 0.96 
    ݓଶ (continuous) ܿଶ = 0.3 0.28 -0.02 0.11 0.11 0.95 
ߤ	  ܾଶ = -0.5 -0.55 -0.05 0.98 0.67 0.92 
    ݒ଴ (intercept) ݀଴ = -0.4 -0.43 -0.03 0.30 0.29 0.97 
    ݒଵ (binary) ݀ଵ = -0.16 -0.15 0.01 0.16 0.16 0.95 
    ݒଶ (continuous) ݀ଶ = 0.5 0.47 -0.03 0.25 0.24 0.96 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
 
Table 3.2. Simulation results using the proposed model to analyze data with no Markov 
Chain effect included on the survival outcome (N=150 subjects, R=1,000, weeks=10) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
ݔଵ (binary) ߚଵ = 0.03 0.30 0.00 0.21 0.21 0.95 ݔଶ (continuous) ߚଶ = -0.2 -0.21 -0.01 0.09 0.09 0.96 
ߣ	  ܾଵ = 0 0.00 0.00 0.81 0.70 0.94 
    ݓ଴ (intercept) ܿ଴ = -0.5 -0.62 -0.12 0.17 0.18 0.90 
    ݓଵ (binary) ܿଵ = 0.1 0.10 0.00 0.15 0.15 0.96 
    ݓଶ (continuous) ܿଶ = 0.3 0.28 -0.02 0.10 0.10 0.95 
ߤ	  ܾଶ = 0 0.01 0.01 0.87 0.67 0.94 
    ݒ଴ (intercept) ݀଴ = -0.4 -0.43 -0.03 0.24 0.25 0.97 
    ݒଵ (binary) ݀ଵ = -0.16 -0.15 0.01 0.15 0.14 0.97 
    ݒଶ (continuous) ݀ଶ = 0.5 0.47 -0.03 0.20 0.21 0.96 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
 
Additionally, we evaluated the performance of the simulated data (Scenario (i) and (ii)) in 
a regular Cox PH model.  The goal for this additional analysis was to further examine the 
simulated data and expect to observe the differences in the longitudinal covariate effect on the 
survival outcome in two scenarios.  When the effect of transition rates on the survival outcome is 
null (i.e., Scenario (ii)), the regular Cox PH model is expected to perform better in Scenario (ii) 
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than in Scenario (i).  Table 3.3 shows the summary of the regular Cox PH model performance in 
each scenario.  Overall, the result in Scenario (i) showed a slightly higher bias on the binary 
variable ݔଵ, while all the other results remained the same in both scenarios. 
 
Table 3.3. Simulation results of the Cox PH model in two scenarios (N=150 subjects, 
R=1,000, weeks=10) 
Covariates in joint 
model 
Parameter true 
value Estimate Bias SD
a SEb 
Coverage 
Probability 
for 95% CI 
Scenario (i). Markov Chain effect on survival outcome. (࢈૚ ് ૙, ࢈૛ ് ૙) 
ݔଵ (binary) ߚଵ ൌ 0.3 0.29 -0.01 0.21 0.21 0.95 
ݔଶ (continuous) ߚଶ ൌ െ0.2 -0.20 0.00 0.09 0.09 0.96 
Scenario (ii). No Markov Chain effect on survival outcome. (࢈૚ ൌ ૙, ࢈૛ ൌ ૙) 
ݔଵ (binary) ߚଵ ൌ 0.3 0.30 0.00 0.21 0.21 0.95 
ݔଶ (continuous) ߚଶ ൌ െ0.2 -0.20 0.00 0.09 0.09 0.96 
aStandard deviation of the point estimates. 
bStandard error, calculated from the average of squared root of estimated variance for each run. 
 
3.4 Application 
3.4.1 Study Population and Description of the Joint Approach 
 We used a longitudinal PRO study (called HN study) with head and neck cancer patients 
recruited from the Head and Neck Clinic at MD Anderson Cancer Center (MDACC) from 
February 2006 to August 2007.  All the patients were 18 years old or older.  Due to the limited 
data collected on patients with other ethnicities (less than 10% of the originally collected data), 
we only used non-Hispanic white patients as a cohort in the analysis.  The study was approved 
by the MD Anderson Institutional Review Board, and all the patients had completed the 
informed consent before the first evaluation of PRO.  The PROs were collected by MDASI-HN 
[32].  Patients completed their MDASI-HN assessment weekly at baseline and the treatment 
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(radiotherapy (RT) or chemoradiotherapy (CRT)) period.  The survival outcome was collected 
from the MDACC medical record system.   
 One hundred eighty one non-Hispanic white patients participated in the study.  Among 
them, 21 patients were excluded from the analysis because the length of PRO repeated 
measurements were not long enough (less than six).  Thus, 160 patients were included in the 
application of the proposed joint approach.  Among these patients, about half (51.52%) received 
radiotherapy (RT) only, and the other half received chemoradiotherapy (CRT).  The average age 
of the selected patients was 58.88 years old, and 21.9% of them were female.  Additionally, one 
fourth (27.81 %) of these patients had late stage (tumor stage III and IV) head and neck cancer.  
The median progression-free survival time was 270 weeks, and the median length of repeated 
PRO measurements was 7 observations. 
In the literature, several studies had been published using this HN cohort.  For example, 
Shi et al. [18] used GBTM (see Section 3.1) to characterize the subjects into several symptom 
severity groups with the average of the top five severe symptoms.  Specially, they used the 
modeled severity membership from GBTM as an outcome in logistic regression to find the 
clinical factors that were associated with the outcome.  Moreover, Rosenthal et al. [33] used 
LMM to evaluate the linear pattern of the symptoms in MDASI-HN between the treatment arms 
(RT vs. CRT), and differences in symptoms such as fatigue, nausea, and disturbed sleep were 
found.  
3.4.1.1 Markov Chain model 
 In order to build a prognostic model, we only selected PRO at baseline and PRO during 
the treatment period in CTMC.  Symptom scores (0-10) were dichotomized to a binary variable 
with a cutpoint at 4 based on previous research [34, 35].  Scores equal to and larger than 4 were 
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defined as moderate/severe level, and scores less than 4 were identified as none/mild level.  The 
transition from none/mild to moderate/severe was termed the worsening rate (ߣ), and the 
transition from moderate/severe to none/mild was called the improving rate (ߤ).  Baseline 
demographical variables and baseline clinical variables were evaluated in CTMC through model 
selection.  The CTMC model was conducted in PROC NLMIXED on SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA). 
3.4.1.2 Cox PH model 
 Progression-free survival (PFS) was used as the main outcome of interest in this 
application.  The survival time is calculated from the end of the treatment period to a survival 
event (progression-free) or to the end of the study (as censored).  We modeled the transition rates 
of a symptom (must be included) and adjusted with baseline covariates in the Cox PH model.   
3.4.2 Model Selection 
 In both CTMC and the Cox PH model, we considered covariates such as demographic 
variables and clinical variables in our model selection.  Demographical variables included age, 
gender (female vs. male), education (high school and above vs. below high school), and 
employment status (employed vs. not employed).  Clinical variables included treatment (CRT vs. 
RT), Eastern Cooperative Oncology Group Performance Status (ECOG-PS, 0 vs. 1+), tumor 
stage, previous induction chemotherapy (yes/no) and radiation dose (standardized). 
The model selection of the proposed joint approach was separated into two steps:   
 Step 1. Covariates in CTMC.  We selected covariates in CTMC using a backward 
approach based on Wald’s test statistics.   
Step 2. Covariates in the Cox PH model.  This step is to identify meaningful clinical 
covariates to the survival outcome while the transition rates of a symptom were included.   
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3.4.3 Results of the Proposed Model 
Table 3.4. Result of the proposed joint approach of Markov Chain 
and Cox PH model applied to the HN study on fatigue 
Covariates in the joint model Estimate SE* Pr > |t| 
Cox PH model 
Gendera  -0.29 0.30 0.34 
Ageb 0.14 0.15 0.36 
Treatmentc -0.73 0.35 0.04 
ߣ (1 10⁄  of a unit) 0.11 0.17 0.52 
ߤ (1 10⁄  of a unit) -0.51 0.21 0.01 
Markov Chain for transition rate ࣅ 
ݓ଴ (intercept) -1.00 0.11 <0.01 
Ageb 0.14 0.11 0.19 
Gendera -0.36 0.23 0.12 
Previous induction chemotherapyd -0.64 0.28 0.02 
Markov Chain for transition rate ࣆ 
ݒ଴ (intercept) -1.52 0.25 <0.01 
Ageb 0.10 0.14 0.49 
Radiation dosee -0.07 0.12 0.52 
Educationf 0.42 0.26 0.11 
Treatmentc -0.55 0.25 0.03 
*Standard error,  afemale vs. male,  bper 11.5 years,  cCRT vs RT,  dyes/no, eper 4.4 
gray,  fhigh school and above vs. below high school. 
 
Several symptoms were used as an application for the proposed joint approach.  
However, to better demonstrate a clinical application of our method, we only present one model 
involving one symptom fatigue which demonstrated strong associations between the transition 
rates and PFS (see Table 3.4).  Age, gender, and treatment were selected to the model for the 
worsening rate ߣ, while age, education, radiation dose, and treatment were included for the 
improving rate ߤ.  In the Cox PH model, the worsening rate ߣ had a positive association with the 
risk of disease progression.  However, the improving rate ߤ had a negative effect on the risk of 
disease progression.  Other covariates that were adjusted in the Cox PH modeling included 
gender, age, and treatment.   
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3.4.3.1 Interpretation of the Transition Rate Effect on the Outcome 
 Transition rates represent the speed of a process from one state to another.  In other 
words, transition rates can also be interpreted as the time consumption between states.  If the 
worsening rate becomes larger, the time of transition from none/mild to moderate/severe will be 
shorter, the patients should also have reported more frequently moderate/severe symptoms.  In 
contrast, if a patient had reported more frequently none/mild levels of a symptom, his/her 
improving rate should be larger.   
In Table 3.4, for a one-tenth of a unit increment of worsening rate (ߣ), a patient’s risk of 
head and neck cancer progression was expected to change by a multiplicity of expሺ0.11ሻ ൌ 1.12 
when other covariates remained constant.  This means the hazard rate of disease progression 
would increase by 12% when there was a 0.1 unit change in the worsening rate.  Similarly, if the 
improving rate (ߤ) increased by a one-tenth unit, a patient’s risk of cancer progression would 
decrease by 40% (expሺെ0.51ሻ ൌ 0.60).  Based on Wald’s test statistics, the p-value of 
improving rate was statistically significant (pvalue=0.01), while the worsening rate did not show 
a significant result (p-value=0.52).  Both transition rates followed proportional hazard 
assumption. 
3.4.3.2 Interpretation of Covariate Effects on the Outcome 
 The interpretation of covariate effects on the outcome in this joint approach depended on 
the inclusion of covariates in each submodel.  If the covariate only existed in the Cox PH model, 
the interpretation of that covariate effect was the same as the regular Cox PH model.  However, 
if a covariate existed in both CTMC and the Cox PH model, the interpretation should include the 
covariate effect through the transition rates in CTMC.  For example, for a unit of standard 
deviation change on age (i.e., 11.5 years), the effect of the progression risk of head and neck 
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cancer is expected to change by a multiplicity of expሺ0.13 ൅ 0.11 ൈ expሺെ1.00 ൅ 0.14 ൈ 1ሻ െ
0.51 ൈ expሺെ1.52 ൅ 0.10 ∗ 1ሻሻ ൌ 1.05.  Therefore, the older the patient, the higher the risk will 
be. 
3.4.3.3  Interpretation of the Covariates to the Transition Rates  
 Some baseline covariates were adjusted in the transition rates of CTMC, and their effect 
on the transition rates was easy to interpret.  For example, treatment was selected only in the 
improving rate at CTMC.  The improving rate was expected to change by a multiplicity of 
expሺെ0.55ሻ ൌ 0.58 when comparing CRT to RT.  The patients who received CRT tended to 
report less none/mild state of fatigue as compared to those receiving RT.  This result is consistent 
with the previous research by Rosenthal et al. [33], who found that CRT patients reported more 
symptom burden than RT patients.  
 
3.5 Discussion 
In this paper, we developed a joint approach of CTMC and the Cox PH model that 
models an observed longitudinal process as covariates to evaluate the effect of the covariates on 
survival.  We validated the two-stage joint approach through simulations and found the model 
performed well in terms of accuracy and precision for two different scenarios.  We also applied 
the proposed joint approach to a PRO study.  The results showed our model was adaptable in 
clinical research, and the interpretation of the transition rates provide a comprehensive way to 
interpret longitudinal PRO when distinct trajectories are observed for each subject.   
 It is noteworthy to discuss the differences among our method, the time-dependent 
covariates in a Cox PH model [29, 36], and the joint modeling that comprised a longitudinal 
model and a survival model [11, 37].  Time-dependent covariates approach in the Cox PH model 
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evaluates the association between a longitudinal covariate and the survival outcome in different 
periods, and the longitudinal process is followed until the survival event occurs.  Similarly, in the 
joint modeling approach, previous studies [11, 37] have built different joint models from a 
longitudinal model (e.g., LMM) and a Cox PH model.  This joint modeling approach also 
measures the longitudinal covariate process along with the survival time.  The survival outcome 
may happen at the same time as the longitudinal process modeled by LMM.  In contrast, we used 
the longitudinal covariate information during the treatment period that would only happen before 
the survival event.  The longitudinal process at the treatment period is considered as the 
information collected before the measurement of the survival time, like other baseline covariates, 
and then this information is used to predict the post-treatment survival events, which makes our 
proposed method a prognostic model.    
Moreover, our proposed method could reduce the dimension of data information in two 
ways.  First, the original scale is reduced from a continuous variable to a binary variable.  When 
the PRO score originally with a 0-10 scale was dichotomized to a binary variable, the 
interpretation of PRO in research becomes more practical in clinical practice.  For example, 
patients who reported score 3 and score 4 were not considered as the same severity level because 
a score 4 would generate further clinical action per the clinical guidance even though there was 
just a one unit difference in scores [38].  With our proposed method, even though we lost some 
information due to the transformation from a continuous variable to a binary variable, this loss is 
acceptable because the binary variable could still provide information on the differences of 
symptom severity levels.  Second, the repeated PRO measurements are reduced to a set of 
transition rates as summary statistics, and then incorporated to the Cox PH model.  This makes 
the proposed joint approach more acceptable to clinical researchers because they can summarize 
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longitudinal PRO as baseline covariates in the Cox PH model as the approach they commonly 
conducted. 
There are other advantages in applying the proposed joint approach.  First, compared to 
GBTM which transformed longitudinal data into membership of grouping, the proposed joint 
approach still presents the change of a longitudinal variable, which makes it suitable to consider 
the longitudinal variable as covariates in the survival model.  Second, CTMC is adequate to the 
random missingness in clinical data collection.  It is true that most studies have pre-specified 
timeline/schedule to collect clinical/PRO data, but a patient may miss a visit/response to the 
study.  When data are missing at random in a longitudinal covariate, CTMC can model the time 
between states.  Third, the proposed joint approach can be easily applied to common statistical 
software such as SAS or R through the two-stage procedure. 
Nevertheless, this joint approach is subject to several limitations.  First of all, lack of 
enough repeated observations in a longitudinal covariate and a small number of covariates 
adjusted in transition rates may lead to an identifiability problem [39, 40] because some patients 
may have the same profile in covariates and the same longitudinal pattern in CTMC.  Moreover, 
the baseline covariates may diminish the effect of transition rates.  In Section 3.4, we opted to 
keep transition rates in the model to maintain the relationship between the longitudinal variable 
and the survival outcome.  However, users can apply different model selection approaches based 
on their research question.      
To conclude, we developed a joint approach of the CTMC and Cox PH model and 
demonstrated that the estimation procedure is valid.  We also applied this approach to a study 
using longitudinal PRO fatigue at baseline and during treatment course on patients with head and 
neck cancer.  The application results indicate the trajectory of fatigue during the treatment period 
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is associated with post-treatment PFS.  Therefore, when distinct trajectories are observed among 
subjects in a longitudinal process, our proposed joint approach is expected to provide an 
alternative to evaluate the effect of a longitudinal process on survival outcomes. 
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4. Journal Article 3 
A Dimension Reduction on Multiple Continuous-Time Markov Chains with Application to 
Longitudinal Patient-Reported Outcomes  
Journal of Applied Statistics 
Keywords: Continuous-Time Markov Chain (CTMC), longitudinal data, factor analysis, 
dimension reduction, patient-reported outcome (PRO) 
 
4.1 Background 
 Factor analysis (FA) has been widely applied to patient-reported outcome (PRO) research 
as a tool when developing PRO instruments to identify unobserved domains.  Most PRO 
instrument validation studies are cross-sectional studies, but PRO studies collecting longitudinal 
data can also be used to examine the unobserved domains over time [1-3].  Specifically, some 
studies [4, 5] used Longitudinal Factor Analysis (LFA) [6] to examine the hidden factors on 
different occasions, but LFA could not address the longitudinal pattern of the original item.  To 
address this issue, in this paper, we propose a novel approach that integrates a two-state 
Continuous-Time Markov Chain (CTMC) to FA, which not only models longitudinal PRO data 
as CTMCs at the individual level but also incorporates the generated transition rates into FA.  
Because the proposed approach applied FA on summary statisticsof longitudinal PRO changes, 
our method is a more comprehensive approach that interprets the underlying construct of 
longitudinal variables.  
Factor Analysis in PRO research  
There are two types of FA, Exploratory Factor Analysis (EFA) and Confirmatory Factor 
Analysis (CFA).  The former is used to explore potential unobserved factors from the observed 
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variables without imposing a preconceived number of factors.  On the other hand, CFA is used to 
test the underlying structure of the observed variables when the unobserved factor structure is 
usually known [7-9].  In this paper, to discover the underlying construct among longitudinal 
variables, we will mainly focus on EFA in PRO research and our proposed method. 
EFA, in fact, has been extensively used in the development of PRO instruments to test 
the reliability of items in an instrument.  For example, Rosenthal et al. [10] have used EFA to 
identify the underlying structure of the cancer symptom items in the MD Anderson Symptom 
Inventory-Head and Neck Module (MDASI-HN).  They found the module items could be 
classified into two factors: one factor included problems with mouth/throat sores, tasting food, 
constipation, problems with teeth or gum, and skin pain/burning/rash; the other factor included 
difficulty with voice or speech, choking or coughing, problems with chewing or swallowing, and 
problems with mucus.  Two other studies [11, 12] also applied EFA in a similar strategy to 
explore the underlying factors among the symptom items in different modules.  Furthermore, 
EFA is also employed in other PRO instrument development or validation studies, such as the 
Medical Outcomes Study Short Form-36 (SF-36) [13, 14],  Functional Assessment of Cancer 
Therapy-General (FACT-G) [15, 16], and Patient-Reported Outcomes Measurement Information 
System (PROMIS) [17, 18].  All of these studies performed EFA on a single occasion, even 
though some [10-12] collected PRO data at more than one event.  However, if longitudinal PRO 
data were analyzed, the underlying structure of the items in the instrument could have provided 
more useful information. 
Longitudinal Factor Analysis   
 Longitudinal factor analysis (LFA) is a special version of structural equation modeling 
(SEM), which is a general statistical modeling technique where a latent factor construct is of 
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interest.  In general, LFA can perform factor analysis across time in a single modeling 
framework by incorporating the correlation among the repeated measurements and 
simultaneously estimating the unobserved factors over time [6].  The result of LFA could show 
the underlying factor structure at each occasion as well as the correlation within the observed 
variables.  LFA has been extensively utilized in psychology.  For example, Corballis and Traub 
[19] proposed a model that can simultaneously estimate two constructs of FA for two occasions, 
and the model considered the relationship between observed variables at two different time 
points.  Then, Joreskog and Sorbom [20], extended the concept and developed a program 
(LISREL), which can perform LFA for multiple occasions (more than two occasions).  
Longitudinal Factor Analysis in PRO Research 
However, only few studies have applied LFA in PRO research.  So far, the Longitudinal 
Analysis of Patient-Reported Outcomes Working Group has summarized their discussion related 
to the methodologies that could be used in future PRO research and commented on the usage of 
LFA in longitudinal PRO work [21].  For example, LFA can be applied to item response theory 
(IRT) [22] models to access the variability of latent structure over time, and distinguish response 
changes due to response shift or true changes.  Another study then used LFA to test the stability 
of the 13-item sense of coherence (SOC) in a longitudinal study on breast cancer patients [4].  In 
this study, Lindblad et al. applied LFA to examine the change of the underlying constructs on 
two occasions.  They concluded that the SOC scale was stable, so it was suitable to measure life 
stress in women with breast cancer.  On the other hand, LFA requires complete data over time, 
and the length of occasions should be the same.  So, if patients have different lengths of repeated 
measurements (such as PROs during the treatment period), only those data that overlapped at the 
same time points can be used in LFA.   
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Continuous-Time Markov Chain 
To accommodate the situation when the lengths of the repeated measurements are 
different for patients, one solution is to apply Continuous-Time Markov Chain at the individual 
level.  Markov Chain models have been applied to studies such as Alzheimer's disease [23, 24] 
and Parkinson’s disease [25, 26] in describing disease progression.  When the disease 
progression status follows the Markov Property, and can be expressed as changes among 
different states, a Markov Chain becomes an appropriate model to estimate those changes among 
the states.  For example, Karlsson et al. used the first-order Markov model to describe changes of 
different sleep levels (lighter sleep vs. deeper sleep) from patients who had insomnia [27], and 
they found the insomnia treatment (temazepam) improved patients’ sleep.  In other applications, 
Markov Chains can also be used to describe the changes of a patient’s disease status over time, 
and then transition rates estimated from these Markov Chains can be incorporated into a second 
model as covariates.  For example, Rubin et al [28] modeled longitudinal intracranial pressure 
(ICP, high ICP vs. normal/low ICP) with Continuous Time Markov Chain (CTMC) as covariates 
in a logistic regression which allowed them to predict the future status of patients with traumatic 
brain injuries.   
In this paper, we will apply CTMC to longitudinal PRO data and describe the changes of 
symptom severity during the treatment period.  Specifically, we will apply a two-state CTMC to 
a longitudinal PRO study that has collected symptom changes in head and neck cancer patients, 
and then incorporates the estimated transition rates from the two-state CTMC to FA to explore 
the underlying factors representing structure in the transition rates.  These factors may be helpful 
because they could reflect longitudinal PRO process during the treatment period, and they may 
indicate whether a symptom change is related to the treatment or to the disease.   
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Next, in Section 4.2, we will describe the two-state CTMC and its estimation procedure.  
FA will also be briefly described in the same section.  Section 4.3 will show how the proposed 
approach could be applied to a real-world study and examines the usage of CTMC in FA.  A 
comprehensive discussion of our proposed method will be held in Section 4.4.  
 
4.2 Method 
4.2.1 Two-State CTMC 
Let ܵ ൌ 1, 2 denote the two-state values for a two-state homogeneous CTMC, and let ࡽ 
be its associated transition rate matrix given by  
ࡽ ൌ ൤െ  െ൨ 
where  is the transition rate from State 1 to State 2, and  is the transition rate from State 2 to 
State 1.  For detailed specification and methodology of CTMC, see textbooks by Ross [29] and 
Pinsky and Karlin [30].  In this paper, we will calculate the transition rates of a two-state time-
homogeneous CTMC for each longitudinal variable and integrate them to FA.  For a CTMC, the 
transition probabilities can be determined by solving a system of differential equations.  When 
the number of states is equal to 2, the explicit formulas for these probabilities are as follows:  
ଵܲଵሺݐሻ ൌ ߤߣ ൅ ߤ ൅
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where ௜ܲ௝ሺݐሻ is the transition probability from State ݅ to State ݆, ݅, ݆ ൌ 1, 2.  Given a length ܶ for 
a longitudinal variable of a subject, the parameters ߣ and ߤ can be estimated using the maximum 
likelihood method.  The individual level likelihood function for a longitudinal variable can be 
written as 
ܮ ൌ ൭ෑܲሾܼሺ0ሻ ൌ ݅ሿூ೔ሾ௓೙ሺ଴ሻሿ
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where ݅ ൌ 1, 2,  
ܫ௜ሾܼሺݐሻሿ ൌ ൜1, ݂݅	ܼሺݐሻ ൌ ݅0, ݋ݐ݄݁ݎݓ݅ݏ݁  
ܲሾܼሺ0ሻ ൌ ݅ሿ is the probability when the initial state is equal to ݅.  For each subject, we will fit a 
two-state CTMC for a longitudinal variable.  Therefore, each subject will have a pair of 
transition rates (ߣ, ߤ), representing the changes of the longitudinal variable. 
Interpretation of transition rate 
 By definition, the transition rate has to be larger than 0 because it represents a moving 
force from one state to another.  When a transition rate increases, the time from one state to 
72 
 
another will be shorter.  For example, let  be the transition rate from State 1 to State 2.  If  is 
higher in one subject, it means time has elapsed 1/ from State 1 to State 2. 
4.2.2 Factor analysis 
Let ܺ be an observed random vector with dimension ݌ ൈ 1.  An orthogonal factor model 
can be expressed as 
ܺ െ ߤ௉ൈଵ ൌ ܮ௣ൈ௠ܨ௠ൈଵ ൅ ߝ௣ൈଵ 
where ݉ ൏ ݌, and ݌ is the number of observed variables.  ݉ is the number of hypothesized 
factors.  ߤ is the mean vector for observed random variable ܺ.  ܮ is the loading matrix for 
factors.  ܨ is a vector with dimension ݉ ൈ 1.  ߝ is a vector for error terms.   
An important assumption of factor analysis is that the hypothesized factors are 
uncorrelated.  This purpose can be achieved by using rotation of the loading matrix.  A 
commonly used rotation method, orthogonal varimax rotation, was applied to this study to ensure 
each variable loads highly on one and only one factor.  Such factor structure will result in each 
factor representing a distinct construct.  The number of ݉ factors can be selected by the methods 
proposed by Bartholomew et al. [31] or Johnson and Wichern [32].  In this paper, the observed 
variables are the transition rates  estimated from the CTMC for each symptom measured in a 
PRO instrument.  Detailed descriptions will be shown in Section 4.3. 
 
4.3 Application 
4.3.1 Study Population and Description of the Proposed Approach 
 We applied the proposed approach, which integrated individual two-state CTMC into FA, 
to a head and neck cancer study.  The study recruited head and neck cancer patients who 
received radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) at MD Anderson Cancer 
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Center from February 2006 to August 2007.  PRO was followed using MDASI-HN [10] at 
baseline (before the treatment) and during each week of treatment.  In the analysis, we only 
included non-Hispanic white patients because less than 10% of subjects were of other 
racial/ethnic background.  All patients signed the informed consent before the first PRO 
evaluation, and the study was approved by the MD Anderson Institutional Review Board. 
 In summary, 181 non-Hispanic white patients were recruited in the study, but 21 patients 
were later excluded because only five repeated measurements of PRO were available.  So, only 
160 patients remained in the final analysis.  Among these 160 patients, about 22% of them were 
female, and the average age was 59 years old.  Also, about half (51%) received the RT in the 
study. 
4.3.2 Implementation 
Individual Two-State Continuous-Time Markov Chain 
 In order to fit the longitudinal PRO in a two-state CTMC, we first dichotomized the 
original scale from 0-10 to a binary variable, according to previous research [33, 34].  The scores 
0-3 were defined as the none/mild level, and scores 4-10 were defined as the moderate/severe 
level.  As a result, the transition rate from none/mild to moderate/severe was called the 
worsening rate (λ), and the transition rate from moderate/severe to none/mild was called the 
improving rate (μ).   
 We used the PRO response collected at baseline and weekly measurements during the 
treatment period to fit the two-state CTMC at the individual level.  Following the methods 
described in Section 4.2.1, we estimated the transition rates for all the symptom items in the 
MDASI-HN of each patient.  That is, for each symptom item, we used two transition rates to 
represent the original repeated measurements.  Note that some patients may not report changing 
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symptom severity levels (none/mild vs. moderate/severe) during the treatment period.  For 
example, a patient may only report disturbed sleep at none/mild level across the entire treatment 
period.  The CTMC, as a result, cannot estimate the worsening rate because no data were 
reported at the moderate/severe level.  In this case, we set a minimum boundary 0.01 for 
transition rates which could not be estimated due to missing transitions.  Additionally, because 
FA assumes normality, we took the natural log of each transition rates before running FA. 
Factor Analysis 
 Once the individual transition rates were generated for each symptom item, we examined 
the proposed approach in two scenarios.  First, we ran FA with both improving rates and 
worsening rates of all symptoms.  This is to test whether the transition rates from CTMC can 
reasonably explain the changes in longitudinal RPO.  Second, we ran FA only with worsening 
rates for all symptoms.  Since the PRO was measured through questions regarding patients’ 
symptom severity, the worsening rates probably could better capture the change of symptoms 
over time for each patient.  All analyses were performed by SAS 9.4 (SAS Institute, Cary, NC). 
4.3.3 Results 
As described in Section 4.3.2, each patient had two transition rates (worsening rate and 
improving rate) for each longitudinal symptom.  Since the distributions of the transition rates are 
not the interest of this paper, we only list the descriptive statistics of the transition rates of each 
symptom in Appendix A.   
Figure 4.1 then showes the result of FA when both worsening rates and improving rates 
were considered in the analysis.  We selected the first two factors because we expected FA to 
distinguish the transition rates by their nature.  It was clear that the majority of the worsening 
rates comprised Factor 1, while the majority of the improving rates comprised Factor 2 except 
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for the symptoms shortness of breath and vomiting.  The loadings for shortness of breath were 
low: 0.16 in Factor 1 and 0.03 in Factor 2, and the loadings for vomiting were also low: 0.12 in 
Factor 1 and 0.06 in Factor 2.  Therefore, FA differentiated the worsening rates and the 
improving rates into different factors.  Detailed loadings on each factors are presented in 
Appendix B.  
Figure 4.2 showed the result of FA when only the worsening rates of symptoms were 
used.  Based on the inflection point in the scree plot, we selected the first two factors.  Factor 1 
included symptoms such as pain, fatigue, nausea, lack of appetite, drowsy, dry mouth, problems 
with mucus, difficulty chewing or swallowing, skin pain/burning/rash, problems with tasting 
food, mouth/throat sores, and problems with teeth or gum.  Overall, Factor 1 represented those 
symptoms that were worse when receiving the treatments (RT or CCRT).  In contrast, Factor 2 
contained symptoms such as disturbed sleep, distress, shortness of breath, remembering, drowsy, 
sadness, vomiting, numbness/tingling, choking/coughing, difficulty in voice or speech, skin 
pain/burning/rash, and constipation.  So, unlike Factor 1, Factor 2 represented the local or 
systemic symptoms that were commonly reported by head and neck cancer patients.   
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Figure 4.1. Factor analysis with both worsening rate and improving rate 
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Figure 4.2. Factor analysis with worsening rates only 
 
 
4.4 Discussion 
 In the previous sections, we showed how to apply individual two-state CTMC with FA.  
Using the individual two-state CTMC to summarize the longitudinal PRO symptoms, we were 
able to decrease the dimension from a longitudinal variable to a set of variables (transition rates) 
as that in a cross-sectional study.  We also inputted these transition rates into FA to explore the 
performance of transition rates and evaluate their representation in the unobserved factors. 
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 When we included both worsening rates and improving rates in FA, the FA could well 
identify the nature of the transition rate.  Worsening rates and improving rates were separated to 
different factors.  The first factor represented worsening rates, and the second represented 
improving rates.  This result validated the application of using two-state CTMC in longitudinal 
variables, and it showed that the transition rates could well represent longitudinal patterns.  Even 
though there were two symptoms, shortness of breath and vomiting, that had low loadings on 
both factors, the overall representation for each factor was still recognizable.   
On the other hand, when we only included the worsening rates in FA, the result of FA 
showed CTMC could sufficiently summarize information from the longitudinal PRO.  As 
indicated in Figure 4.2, Factor 1 represented those worsening rates of symptoms related to the 
treatment (radiotherapy or chemoradiotherapy), and the remaining worsening rates of symptoms 
were categorized to Factor 2, which may represent the systemic symptoms of head and neck 
cancer.  Notably, the worsening rate of drowsiness and the worsening rate of skin 
pain/burning/rash had effects on both factors.  In particular, the result from Figure 2 was 
consistent with the previous literature.  For example, Bossi et al. [35, 36] reported pain (called 
breakthrough cancer pain) were observed during the RT or CCRT among head and neck cancer 
patients.  Also, another study found fatigue was related to the dose of RT [37].  In that study, 
patients who received higher dose of radiation reported fatigue after the treatment.  Other 
symptoms including mouth sores, dry mouth, difficulty in swallowing, change in tasting food, 
lack of appetite, rash on skin, and stiff jaw were also common side effects for patients who 
received RT.  Moreover, a previous study [1] that used the same dataset as ours reported the 
distribution of each MDASI-HN symptom item during the treatment period.  Compared with 
their distributions, the symptom worsening rates in the first factor in our study (Figure 4.2) were 
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actually the items that had been significantly increased during the treatment period in their study.  
Patients were asymptomatic at baseline and experienced worsening symptoms during their 
treatment course.  This means those worsened symptoms may have been caused by side effects 
of the treatment.  Furthermore, in Figure 2, we only used the worsening rate in FA because 
patients who filled MDASI-HN were only asked to report the most severe symptom level in the 
past 24 hours.  Thus, the worsening rate alone could disclose patients’ symptom severity during 
the treatment period and help to simplify the interpretation of results in FA.   
  Compared to the LFA [6], our method provides a simpler, more comprehensive 
interpretation when conducting a factor analysis in a longitudinal study.  LFA could produce the 
underlying construct at different occasions by adjusting the correlation from repeated 
measurements.  Thus, the way to interpret of the result from LFA is like interpreting the result 
from FA multiple times.  In contrast, our proposed method summarizes the longitudinal 
information as a set of variables (transition rates), and then applies these variables to FA as those 
in a cross-sectional study.  Therefore, the interpretation of the results from our method is the 
same as the interpretation in other studies applying FA in a cross-sectional study.  However, our 
interpretation is based on the worsening rate or improving rate of a symptom.   
There are other advantages of our proposed method.  First, our method can handle the 
missing data in the repeated measurements.  The CTMC models the transition based on the time 
between two observed states, and the length of the longitudinal data can be different because we 
model CTMC at the individual level.  Besides, the two-state CTMC can be easily modeled using 
popular statistical programs such as SAS and R by specifying the likelihood described in Section 
4.2.1, and the factor analysis is supported in most statistical programs. 
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 One of the limitations of our proposed approach is information loss through 
dichotomization of the original scale on PRO.  In the two-state CTMC, we dichotomized the 
original scale (0-10) to a binary variable (none/mild vs. moderate/severe).  So, we may lose 
information on the original scale, but a binary ordinal scale can still provide sufficient 
information on the severity of patients’ symptoms.  Second, the cut point selected for the 
dichotomization of the symptom scales is critical and needs more consideration.  In this study, 
we used score 4 as the cut point because previous studies [33, 34] showed score 4 performed 
well when differentiating symptoms such as fatigue and pain.  However, if a symptom or a PRO 
measurement has other preferable cut points, users can apply different cut points based on their 
research interest.  As the cutpoint 4 has been recommended by multiple NCCN and ASCO 
guidelines for symptom management [33, 38-41], the current results are interpretable for further 
clinical application when symptom monitoring is implemented for patients under active cancer 
treatments.  Third, for patients who only reported symptoms in the same severity level, we set an 
arbitrary boundary 0.01 for the corresponding transition rates based on the length of the 
treatment period in the study.  As a result, some of transition rate estimates may not directly 
reflect the true change in the longitudinal process.  However, this situation may be improved 
when PRO is collected over longer periods because, in this scenario, the probability of no 
transition will be substantiously reduced.    
To conclude, we propose a new approach that can comprehensively summarize 
information from longitudinal PRO studies.   Our method uses the two-state CTMC at the 
individual level to summarize the changes of longitudinal PRO information, and then integrates 
those estimated transition rates into FA to explore the underlying construct among symptoms.  
We showed that our approach could provide meaningful clinical information through the 
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transition rates, and the result of FA proved the utility of CTMC in longitudinal PRO data.  It is 
expected that this approach can help researchers who are developing PRO instruments and 
needing a solution to explain the underlying construct of instrument items when the longitudinal 
PRO process is considered.  
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Appendix A  
Table 4.1. Distributions of worsening rate and improving rate 
of symptoms in MDASI-HN 
Transition rate Mean Std. Q1 Median Q3 
ࣅ࢖ࢇ࢏࢔  2.00 3.30 0.19 0.38 2.09 
ࣆ࢖ࢇ࢏࢔  2.09 3.49 0.01 0.53 2.39 
ࣅࢌࢇ࢚࢏ࢍ࢛ࢋ  2.56 3.68 0.20 0.55 4.40 
ࣆࢌࢇ࢚࢏ࢍ࢛ࢋ  1.86 3.34 0.01 0.49 1.83 
ࣅ࢔ࢇ࢛࢙ࢋࢇ  1.43 2.43 0.01 0.22 1.84 
ࣆ࢔ࢇ࢛࢙ࢋࢇ  2.72 4.18 0.44 0.56 3.67 
ࣅ࢙࢒ࢋࢋ࢖  1.85 3.17 0.01 0.35 2.48 
ࣆ࢙࢒ࢋࢋ࢖  2.41 3.77 0.34 0.56 3.14 
ࣅࢊ࢏࢙࢚࢘ࢋ࢙࢙  1.30 2.38 0.01 0.01 1.57 
ࣆࢊ࢏࢙࢚࢘ࢋ࢙࢙  2.59 4.12 0.52 0.56 2.55 
ࣅ࢙ࢎ࢕࢚࢘࢈࢘ࢋࢇ࢚ࢎ  0.72 2.20 0.01 0.01 0.01 
ࣆ࢙ࢎ࢕࢚࢘࢈࢘ࢋࢇ࢚ࢎ  1.47 2.56 0.53 0.55 0.59 
ࣅ࢘ࢋ࢓ࢋ࢓࢈ࢋ࢘  0.76 2.02 0.01 0.01 0.07 
ࣆ࢘ࢋ࢓ࢋ࢓࢈ࢋ࢘  1.78 3.53 0.53 0.55 0.61 
ࣅࢇ࢖࢖ࢋ࢚࢏࢚ࢋ  2.49 3.68 0.08 0.39 3.91 
ࣆࢇ࢖࢖ࢋ࢚࢏࢚ࢋ  1.92 3.12 0.01 0.54 1.97 
ࣅࢊ࢘࢕࢙࢝࢟  1.75 3.17 0.01 0.32 1.76 
ࣆࢊ࢘࢕࢙࢝࢟  2.10 3.55 0.01 0.54 1.43 
ࣅࢊ࢘࢟࢓࢕࢛࢚ࢎ  2.49 4.08 0.23 0.39 4.43 
ࣆࢊ࢘࢟࢓࢕࢛࢚ࢎ  1.58 3.08 0.01 0.16 1.19 
ࣅ࢙ࢇࢊ  1.01 2.16 0.01 0.01 0.60 
ࣆ࢙ࢇࢊ  1.90 3.49 0.52 0.55 0.63 
ࣅ࢜࢕࢓࢏࢚࢏࢔ࢍ  0.95 2.10 0.01 0.01 0.39 
ࣆ࢜࢕࢓࢏࢚࢏࢔ࢍ  2.51 4.41 0.53 0.56 0.75 
ࣅ࢔࢛࢓࢈࢔ࢋ࢙࢙  0.44 1.19 0.01 0.01 0.01 
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ࣆ࢔࢛࢓࢈࢔ࢋ࢙࢙  1.62 2.82 0.53 0.56 0.61 
ࣅ࢓࢛ࢉ࢛࢙  2.08 3.64 0.19 0.35 2.63 
ࣆ࢓࢛ࢉ࢛࢙  2.02 3.41 0.01 0.47 1.92 
ࣅࢉࢎࢋ࢝࢏࢔ࢍ  2.23 3.66 0.19 0.34 2.26 
ࣆࢉࢎࢋ࢝࢏࢔ࢍ  1.84 3.40 0.01 0.53 1.94 
ࣅࢉࢎ࢕࢑࢏࢔ࢍ  1.25 2.35 0.01 0.14 1.67 
ࣆࢉࢎ࢕࢑࢏࢔ࢍ  2.66 4.15 0.52 0.56 2.47 
ࣅ࢜࢕࢏ࢉࢋ  1.08 2.09 0.01 0.19 0.63 
ࣆ࢜࢕࢏ࢉࢋ  2.20 3.92 0.50 0.55 1.20 
ࣅ࢙࢑࢏࢖ࢇ࢏࢔  1.34 2.23 0.01 0.28 1.66 
ࣆ࢙࢑࢏࢖ࢇ࢏࢔  2.85 4.67 0.01 0.56 2.89 
ࣅࢉ࢕࢔࢙࢚࢏࢖ࢇ࢚࢏࢕࢔  1.44 2.82 0.01 0.01 1.48 
ࣆࢉ࢕࢔࢙࢚࢏࢖ࢇ࢚࢏࢕࢔  2.57 3.81 0.53 0.57 2.78 
ࣅ࢚ࢇ࢙࢚ࢋࢌ࢕࢕ࢊ  2.16 3.80 0.23 0.38 2.17 
ࣆ࢚ࢇ࢙࢚ࢋࢌ࢕࢕ࢊ  1.10 2.54 0.01 0.01 0.58 
ࣅ࢓࢕࢛࢚ࢎ࢙࢕࢘ࢋ  2.03 3.39 0.18 0.33 2.78 
ࣆ࢓࢕࢛࢚ࢎ࢙࢕࢘ࢋ  2.18 3.72 0.01 0.54 2.05 
ࣅ࢚ࢋࢋ࢚ࢎ  1.10 2.13 0.01 0.15 1.32 
ࣆ࢚ࢋࢋ࢚ࢎ  2.70 4.15 0.53 0.57 3.83 
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5. CONCLUSION AND FUTURE RESEARCH 
We have developed models using two-state CTMCs to depict longitudinal PRO 
trajectories and incorporated transition rates in survival modeling and factor analysis.  The 
novelty of our research is that the dynamic longitudinal process has been transformed to cross-
sectional transition rates.  These rates can be interpreted as the inverse of average durations taken 
during the transitions from one state to another.  Additionally, these transition rates adjusted with 
baseline covariates will also help to explain the change over time for each individual patient.  
Specifically, in this research, we built a joint model that combines the longitudinal PRO process 
in a two-state CTMC with a parametric survival model (Weibull Regression) when the survival 
time is the outcome of interest.  Besides, another semi-parametric modeling involving a two-state 
CTMC and the Cox PH model was also developed when the risk of a survival event is the 
primary outcome.  Moreover, CTMCs were integrated to factor analysis when the unobserved 
symptom construct was the main interest such as that in a PRO instrument development process.   
In simulation studies, we validated the estimation procedures of our proposed models and 
demonstrated the application of our models in the setting when a longitudinal process was used 
to predict time to an event.  Specifically, in Section 2, we used a two-state CTMC to describe the 
longitudinal symptom (cancer fatigue) during the chemotherapy period in lung cancer patients.  
The transition rates were used as covariates to predict the overall survival in a joint modeling 
framework.  In Section 3, the longitudinal patient-reported fatigue during the 
radiation/chemoradiation period was then modeled as a CTMC and used to model the risk of 
head and neck cancer progression in a joint approach.  Both applications showed that our 
proposed models could be applicable in clinical research to address the association between the 
longitudinal PRO and survival outcomes.     
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What is more, we further illustrated the usage of CTMC in longitudinal PROs for the 
method of dimension reduction in Section 3.  We built the individual two-state CTMC for each 
patient to describe their symptoms during treatment and used the generated transition rates for 
each symptom as summary statistics, which function as the observed variables in factor analysis.  
The results showed that the transition rates could explain the longitudinal symptom patterns 
appropriately and provide sufficient information in the factor analysis for the underlying 
symptom construct.   
In this dissertation, the major limitations of our research are discussed.  However, some 
of them can be addressed in future research.  First of all, we lost partial information when we 
dichotomized the longitudinal variable (a continuous or ordinal variable) into a binary variable in 
the two-state CTMC.  Even though we have addressed this issue before (see discussion in 
Section 2 and Section 3), categorizing more states in the CTMC and turning it to a three-state 
CTMC or four-state CTMC could mitigate the problem.  In fact, if large variation among the 
states was observed, a three-state CTMC, for example, may be more appropriate to illustrate the 
longitudinal process.  Therefore, a future joint modeling method that combines a three-state 
CTMC and the survival model may be of interest.  Second, we adjusted baseline covariates in the 
two-state CTMC, but the missing data mechanism of the baseline covariates was not discussed in 
this research.  It is common that a missing clinical variable may occur in real-world data 
collection; therefore, it is worth exploring further different approaches used for missing data 
mechanisms and their effect on parameter estimation in the joint modeling.  Third, we linked a 
longitudinal process to a survival outcome in this research; however, a broader joint modeling 
approach could include two or more longitudinal processes may accommodate the needs of PRO 
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research when multiple PROs are of interest at the same time.  Lastly, we used a two-step 
backward selection strategy for model selection in the joint model we proposed, but the 
comprehensive associations among the longitudinal process, baseline covariates, and the survival 
outcome were not discussed in this research.  For example, the PRO (the longitudinal process) 
may serve as a confounder or serve as a mediator to the survival outcome.  Therefore, further 
research that explicitly studies the association among the longitudinal process, baseline 
covariates, and survival outcome can help to guide the strategy used in the model selection.           
 So far, to our knowledge, this is the first study where CTMC was applied to PRO 
symptom research.  Most of the previous studies used a linear mixed model to describe the 
longitudinal PRO trend, but they were incapable of fitting the data when distinct trajectories 
were observed.  In contrast, CTMC could better depict the longitudinal PRO pattern, and it is 
also suitable and practical for it to be applied to other statistical models in clinical research. 
 In summary, we developed statistical methods that model a longitudinal PRO process as a 
two-state CTMC and integrate it to the survival models or factor analysis.  The applications 
showed that the covariate-adjusted transition rates could summarize longitudinal PROs 
appropriately and serve as predictors in the survival analysis.  Furthermore, we also 
demonstrated an alternative to reduce the dimension of longitudinal patient-reported symptoms 
using CTMC.  Therefore, with our proposed method, researchers can better understand the 
unobserved longitudinal symptom construct in a much simpler manner.    
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